



Government **B**ioscience **G**rants

UPDATED MONTHLY

August 11, 2020

—  
THE ESSENTIAL GUIDE TO

# Non-Dilutive Government Funding


PUBLISHED BY



## Questions?

Liz Powell, Esq., MPH  
lpowell@G2Gconsulting.com

 [www.G2Gconsulting.com](http://www.G2Gconsulting.com)

 [@G2Gconsulting](https://twitter.com/G2Gconsulting)





GOVERNMENT BIOSCIENCE GRANTS

[www.G2Gconsulting.com/bioscience-corner](http://www.G2Gconsulting.com/bioscience-corner)

## GBG Report

**Updated Monthly**

August 11, 2020

**August 21, 2020 from 10:00am-10:30am** – Join us for [G2G’s Monthly GBG Report Highlights Call & Screen Share](#) where we give an interactive high-level review of funding opportunities in this month’s report and an informal dialogue on securing non-dilutive federal government funding to help grow your business and answer questions you may have about the funding process. Click [here](#) to register.

**August 1-31, 2020** – [BARDA](#) is accepting applications from biotech, pharmaceutical, and small businesses to present innovative medical countermeasure (MCM) treatments and products at this year’s virtual [BARDA Industry Day](#) during the [Lightning Talks](#) segment on October 27, 2020. Click [here](#) to submit your MCM technology; and if selected, you will get 6 minutes to present your technology to an audience of government and industry officials and experts.

	Title (Agency)	Opp. Number	Description	Deadline	Funding Level	Link
			<b>ALCOHOL ABUSE (4)</b>			
1.	Pre-Announcement INIA Research Resource (U24 Clinical Trial Not Allowed/U01 Clinical Trial Optional) (NIH)	NOT-AA-20-014; 015; 016	The National Institute on Alcohol Abuse and Alcoholism (NIAAA) intends to renew an initiative by publishing a FOA to solicit applications for Administrative Resources - Cooperative Agreements (U24) to provide administrative support to collaborative research projects (U01) and research resource cores (U24) as part of a Consortium on the Integrative Neuroscience Initiative on Alcoholism (INIA). The goal of INIA is to investigate brain mechanisms of excessive alcohol drinking and related phenotypes associated with alcohol use disorder (AUD). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.	Estimated Post Date: 10/15/20  Estimated Proposal Due Date: 5/18/21	Up to \$500,000, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328516">https://www.grants.gov/web/grants/view-opportunity.html?opId=328516</a>  <a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328517">https://www.grants.gov/web/grants/view-opportunity.html?opId=328517</a>  <a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328518">https://www.grants.gov/web/grants/view-opportunity.html?opId=328518</a>

2.	Pre-Announcement Promoting Population Health through Increased Capacity in Alcohol Epidemiology & the Prevention of Excessive Alcohol Use (CDC)	CDC-RFA-DP21-2105	<p style="text-align: center;"><b>ALCOHOL ABUSE</b></p> <p>The purpose of this NOFO is to build capacity in alcohol epidemiology in states and provide the tools and information needed to perform core public health functions related to excessive alcohol use prevention in states. This increased epidemiologic capacity will help build the public health infrastructure that is needed to reduce excessive alcohol use – a leading preventable cause of death in the U.S. The NOFO includes an additional component with one recipient for the delivery of expert technical assistance and training on population-level evidence-based strategies for preventing excessive alcohol use and related harms in states and communities, such as those recommended by the Community Preventive Services Task Force.</p>	<p>Estimated Post Date: 3/31/21</p> <p>Estimated Proposal Due Date: 4/30/21</p>	<p>Up to \$300,000 per year, for up to 5 years</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328583">https://www.grants.gov/web/grants/view-opportunity.html?opId=328583</a></p>
<b>ALZHEIMER'S DISEASE &amp; DEMENTIA (19)</b>						
3.	Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional) (NIH)	RFA-AG-21-029; 069	<p>This FOA invites applications that apply a cross-disciplinary and team science approach to gain comprehensive mechanistic understanding of the impact of sex differences on the trajectories of brain aging, phenotypes, and risk of Alzheimer's Disease (AD) and AD-related dementia (ADRD), and on precision medicine for treatment and prevention of AD/ADRD, including the responsiveness to pharmacologic and non-pharmacologic interventions. The central goal of this initiative is to develop robust research programs that will explore how genes, environment, and hormonal status (gonadal and brain-derived) interact at various levels of biologic complexity (cell, tissue, organs/organ systems, and populations) to produce heterogeneous phenotypes of disease risk and responsiveness to therapy in AD/ADRD.</p>	<p>Letter of Intent Due: 10/10/20</p> <p>Proposal Due Date: 11/10/20</p>	<p>Up to \$750,000 per year, for up to 5 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-029.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-029.html#_Section_II_Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-269.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-269.html#_Section_II_Award_1</a></p>

4.	<p>Notice of Special Interest:  Fundamental and Translational Research on Decision Making in Aging and/or Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) (NIH)</p>	<p>NOT-AG-20-039  PA-20-183;  184;  185;  194;  195;  196</p>	<p style="text-align: center;"><b>ALZHEIMER'S DISEASE &amp; DEMENTIA</b></p> <p>Research is sought that characterizes the extent to which behavioral, psychological, and neural processes involved in decision making are differentially impacted in normal aging, MCI, and AD/ADRD. Investigations that target the influence of social factors on decision making or other factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse are of particular interest. This NOSI also encourages preclinical and applied research on decision making that may facilitate the design of decision-supportive interventions for midlife and older adults with and without MCI and AD/ADRD. Specific opportunities include the development of decision-support interventions to leverage cognitive, emotional, social, and motivational strengths of these populations; tools to assess decisional capacities; strategies for simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices The use of animal models to explore the neural basis of affective, cognitive, social, and motivational parameters as they relate to age-related changes in decision making is also invited. Submit applications for this initiative using the listed funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice.</p>	<p>Proposals accepted on a rolling basis until 1/8/22</p>	<p>Dependent upon award mechanism</p>	<p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-039.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-039.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html#_Section II. Award 1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html#_Section II. Award 1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section II. Award 1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-194.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-194.html#_Section II. Award 1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html">https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-196.html">https://grants.nih.gov/grants/guide/pa-files/PA-20-196.html</a></p>
----	---	---	--	---	---------------------------------------	--

5.	Notice of Special Interest: Sex and Gender Differences in Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (NIH)	NOT-AG-20-038  PAR-19-070; 071	<p style="text-align: center;"><b>ALZHEIMER'S DISEASE &amp; DEMENTIA</b></p> <p>This NOSI is intended to promote multidisciplinary research to clarify sex and gender differences in the risk, development, progression, diagnosis, and clinical presentation of Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD). Studies that examine sex and gender differences in outcomes (e.g., clinical, functional, well-being) among people living with AD/ADRD are also relevant. Broad areas of interest include biological (e.g., hormonal, genetic, metabolic, comorbidity-related), neuroscientific (e.g., neural systems and functions), behavioral (e.g., physical activity, substance use, social engagement), social (e.g., history of maltreatment or adversity, child rearing, marital status, education, employment), psychological (e.g., depression, cognitive ability, emotional function, stress reactivity, personality), and healthcare profession (e.g., provider knowledge and attitudes about dementia) and healthcare system-level (e.g., access to care) factors and processes that separately or together may drive observed differences by sex and gender and/or may operate differently by sex and gender. Studies that account for methodological and measurement issues that may drive sex and gender differences are also of interest. Submit to FOAs PAR-19-070 or PAR-19-071</p>	Proposal Due: 11/12/20 3/11/21 7/9/21	Dependent upon proposal and award mechanism, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-038.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-038.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/par-19-070.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/par-19-070.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/par-19-071.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/par-19-071.html#_SectionII.Award1</a>
----	---	---	--	--	--	---

6.	Notice of Special Interest: Basic and Translational Research on Affective, Motivational, and Social Function in Normative Aging and/or Alzheimer's Disease and Related Dementias (AD/ADRD) (NIH)	NOT-AG-20-040 PA-20-183; 184; 185; 194; 195; 196	<p style="text-align: center;"><b>ALZHEIMER'S DISEASE &amp; DEMENTIA</b></p> <p>NIA's goals are three-fold: (1) to advance understanding of normative maturational changes in affective, motivational, and social processes, their role in behavior and cognition, and their underlying integrative neural-behavioral mechanisms; (2) to elucidate how dysfunction in these processes might manifest in MCI and the early stages of AD/ADRD; and/or (3) to determine how dysfunction in these processes might account for any of the Behavioral and Psychological Symptoms of Dementia (BPSD) observed in AD/ADRD. Such studies may identify novel targets for preventative or therapeutic interventions to promote social, emotional, and cognitive well-being; facilitate adaptive function in aging; normalize social or emotional dysregulation; and/or strengthen social or emotional resilience at different stages of the life course and at different disease stages in AD/ADRD.</p>	Proposals accepted on a rolling basis until 1/8/22	Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-039.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-039.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-194.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-194.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html">https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-196.html">https://grants.nih.gov/grants/guide/pa-files/PA-20-196.html</a>
----	--	--	--	--	--------------------------------	---

7.	Mechanisms of Pathological Spread of Abnormal Proteins in LBD and FTD (R01 Clinical Trial Not Allowed) (NIH)	RFA-NS-21-006	<p style="text-align: center;"><b>ALZHEIMER'S DISEASE &amp; DEMENTIA</b></p> <p>This FOA invites research on the mechanism(s) by which abnormal proteins spread throughout the nervous systems of patients with Frontotemporal Dementia and/or Lewy Body Dementia. Applications that move beyond a focus on one mechanism of spread to consider how spreading might proceed in the context of multiple proteinopathies, multiple cell/circuit types, and multiple pathways are of particular interest. This funding opportunity announcement seeks applications that examine how abnormal proteins spread throughout the nervous system in patients with LBD or FTD.</p>	Proposal Due: 10/27/20	Dependent on proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-006.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-006.html#_Section_II_Award_1</a>
<b>AUGMENTED REALITY (1)</b>						
8.	NIST Public Safety Innovation Accelerator Program – Augmented Reality (DOC)	2020-NIST-PSIAP-AR	The NIST's Public Safety Innovation Accelerator Program (PSIAP) is seeking applications from eligible applicants for activities to enhance augmented reality (AR) capabilities in support of first responder operations. The PSIAP-AR aims to attract experts and innovators from industry and academia to focus on conducting research and development of visual interfaces through the use of AR technology. The goals and outcomes of this funding opportunity will be improving the general usability and ecosystem of AR applications and technology built around the public safety use case. This funding opportunity extends across multiple PSCR research areas and includes additional objectives under cybersecurity, resiliency, and location-based services domains.	Proposal Due: 10/1/20	Up to \$600,000 per year, for up to 2 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328473">https://www.grants.gov/web/grants/view-opportunity.html?opId=328473</a>  (For Full Announcement see Related Documents Tab)
<b>ARTHRITIS (1)</b>						
9.	Pre-Announcement Advancing Arthritis Public Health Priorities through National Organizations (CDC)	CDC-RFA-DP21-2106	This NOFO will leverage and expand existing systems, technologies and networks with national reach and/or access into large segments of the adult population to sustainably increase awareness and availability of and participation in arthritis-appropriate, evidence-based interventions (AAEBIs). It will also support technical assistance to state health departments and provision of arthritis-specific consumer health information to the public.	Estimated Post Date: 1/22/21  Estimated Proposal Due Date: 4/5/21	Up to \$500,000, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328396">https://www.grants.gov/web/grants/view-opportunity.html?opId=328396</a>

<b>BIOMEDICAL DATA MANAGEMENT (3)</b>						
10.	The NINDS Human Biospecimen and Data Repository (U24 Clinical Trial Not Allowed) (NIH)	RFA-NS-20-031	This FOA invites applications to serve as the National Institute of Neurological Disorders and Stroke (NINDS) Human Biospecimen and Data Repository in Neurological Disorders. This repository will maintain the current collection of biospecimens as well as support expansion of the collection in accordance with the NINDS mission. The NINDS Human Biospecimen and Data Repository will distribute biospecimens broadly to qualified academic and industry researchers to advance basic, translational and clinical research in neurological disorders including stroke and traumatic brain injury.	Letter of Intent Due: 9/20/20  Proposal Due 10/20/20	Up to \$1.5 million, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-031.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-031.html#_SectionII.Award1</a>
11.	BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional) (NIH)	RFA-MH-20-600	This FOA solicits applications to develop web-accessible data archives to capture, store, and curate data related to BRAIN Initiative activities. The data archives teams will work with the research community to incorporate tools that allow users to analyze and visualize the data, but the creation of such tools is not part of this FOA.	Letter of Intent Due: 6/14/21  Proposal Due: 7/14/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-600.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-600.html#_SectionII.Award1</a>
12.	Computational and Data-Enabled Science and Engineering in Mathematical and Statistical Sciences (CDS&E-MSS) (NSF)	20-8069	The CDS&E-MSS program accepts proposals that engage with the mathematical and statistical challenges presented by (1) the ever-expanding role of computational experimentation, modeling, and simulation on the one hand, and (2) the explosion in production and analysis of digital data from experimental and observational sources on the other. The goal of the program is to promote the creation and development of the next generation of mathematical and statistical software tools, and the theory underpinning those tools, that will be essential for addressing these challenges. This program is part of the wider NSF <a href="#">Computational and Data-enabled Science and Engineering (CDS&amp;E) enterprise</a> .	Proposal Due: 9/15/20	Dependent upon proposal	<a href="https://www.nsf.gov/funding/pgm_sum.m.jsp?pims_id=504687">https://www.nsf.gov/funding/pgm_sum.m.jsp?pims_id=504687</a>
<b>BROAD AGENCY ANNOUNCEMENTS (23)</b>						
13.	BARDA Broad Agency Announcement (HHS)	BAA-18-100-SOL-00003	The BARDA Broad Agency Announcement will not allow submissions of white papers or full proposals for any of the research areas of interest until further notice. Due to our response to the SARS-CoV-2 virus and the necessity to prioritize resources, only submissions to special instructions for efforts that directly support our response to SARS-CoV-2 or the COVID-19 disease will be accepted. While we regret this action, it is required to focus BARDA's efforts on the immediate need. This policy will continue indefinitely.	White Papers Due: 10/31/20	Dependent upon proposal	<a href="https://www.mediccountermeasures.gov/barda/barda-baa/">https://www.mediccountermeasures.gov/barda/barda-baa/</a>  <a href="https://beta.sam.gov/opp/d1b6e601426e4e4c943235babdd4133a/view">https://beta.sam.gov/opp/d1b6e601426e4e4c943235babdd4133a/view</a>



14.	Strategic Technologies Office Broad Agency Announcement (DoD/DARPA)	HR00112 0S0034	<p align="center"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>DARPA's Strategic Technology Office (STO) is seeking innovative ideas and disruptive technologies that provide the U.S. military increased lethality in an era of eroding dominance within the focus areas of the broader Mosaic Warfare objective: Mosaic Technologies, Mosaic Effects Web Services (EWS), and Mosaic Experimentation. Proposed research should investigate approaches that enable revolutionary advances in science, devices, or systems. The Defense Advanced Research Projects Agency (DARPA) anticipates funding a limited number of proposals under this BAA. Specifically excluded are existing mature solutions and research that primarily results in evolutionary improvements to existing technologies.</p>	Proposal Due: 3/1/21	Dependent upon proposal	<a href="https://beta.sam.gov/opp/6b61760cf1914dd4baef3ce23fdc991c/view">https://beta.sam.gov/opp/6b61760cf1914dd4baef3ce23fdc991c/view</a>
15.	USAMRDC Broad Agency Announcement for Extramural Medical Research (DoD)	W81XW H18SBA A1	This BAA supports extramural research and development ideas for basic and applied research to support scientific study and experimentation directed toward advancing the state of the art or increasing knowledge or understanding rather than focusing on development of a specific system or hardware solution. Research and development funded through this BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease Research Program; Combat Casualty Care Research Program; Military Operational Research Program; Clinical and Rehabilitative Medicine Research Program; Medical Biological Defense Research Program; Medical Chemical Defense Research Program; Medical Simulation and Information Sciences Research Program.	No Due Dates, open until 9/30/22  Pre-application Required  Full Proposal by invitation	Dependent upon proposal, for up to 5 years	<a href="https://www.grants.gov/web/grants/search-grants.html">https://www.grants.gov/web/grants/search-grants.html</a> (Full Announcement in Related Documents Tab)

16.	U.S. Army Research Institute for the Behavioral and Social Sciences (ARI) Broad Agency Announcement for Basic, Applied, and Advanced Research (DoD)	W911NF-18-S-0005	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>Programs funded under this BAA include basic research, applied research, and advanced technology development that can improve human performance and Army readiness. Funding of R&amp;D within ARI areas of interest will be determined by funding constraints and priorities set during each budget cycle. Topic areas of basic research interest include: Understanding Team Dynamics; Improving Leadership and Leader Development; Identifying, Assessing, and Assigning Quality Personnel; Enhancing Lifelong Learning. ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology.</p>	No Due Dates, open until 4/29/23  Full Proposal Required	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=304462">https://www.grants.gov/web/grants/view-opportunity.html?opId=304462</a>  (Full Announcement in Related Documents Tab)
17.	Army Research Office Broad Agency Announcement for Fundamental Research (DoD)	W911NF-17-S-0002-07	The purpose of this Broad Agency Announcement (BAA) is to solicit research proposals in the engineering, physical, life, and information sciences for submission to the Army Research Office (ARO) for consideration for possible funding. ARL has an overarching technical strategy to support Strategic Land Power Dominance for the Army of 2030 and beyond. The strategy is based on seven Science and Technology (S&T) Core Technical Competencies: Computational Sciences, Ballistics Sciences, Materials & Manufacturing Sciences, Protection Sciences, Propulsion Sciences, Network & Information Sciences and Human Sciences.	No Due Dates, open until 3/31/22	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2020/04/ARO-BAA-Amendment-7-Final.pdf">https://www.arl.army.mil/wp-content/uploads/2020/04/ARO-BAA-Amendment-7-Final.pdf</a>
18.	Army Research Office Broad Agency Announcement Staff Research Program (DoD)	W911NF 20S0003	The ARO is soliciting proposals for Staff Research Program opportunities. The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. The staff research will be performed collaboratively with institutions external to ARO. Staff research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences, when there is an intersection with the interests and capabilities of the participating external institutions in these basic research areas.	No Due Dates, open until 2/19/25	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf">https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf</a>

19.	Army Research Laboratory Broad Agency Announcement for Basic and Applied Scientific Research (DoD)	W911NF-17-S-0003	<p align="center"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>The ARL BAA seeks proposals from institutions of higher education, nonprofit organizations, state and local governments, foreign organizations, foreign public entities, and for-profit organizations (i.e. large and small businesses) for research based on the following S&amp;T campaigns: Computational Sciences, Materials Research, Sciences for Maneuver, Information Sciences, Sciences for Lethality and Protection, Human Sciences, and Assessment and Analysis. Further details are described in the ARL Technical Strategy and in the ARL S&amp;T Campaigns located at <a href="http://www.arl.army.mil">www.arl.army.mil</a>. These documents are subject to periodic refinements which may result in taxonomy inconsistencies. These inconsistencies should not affect the efficacy of the BAA to present a complete portfolio of essential ARL research.</p>	No Due Dates, open until 3/31/22	Dependent upon proposal	<a href="https://www.arl.army.mil/wp-content/uploads/2019/11/arl-baa-ARL-BAA-W911NF-17-S-0003-Amendment-07-2-6-19.pdf">https://www.arl.army.mil/wp-content/uploads/2019/11/arl-baa-ARL-BAA-W911NF-17-S-0003-Amendment-07-2-6-19.pdf</a>
20.	The USAID Global Health Broad Agency Announcement for Research and Development (2018) (USAID)	GLOBAL HEALTH -BAA-2018	This FOA seeks opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address the most pressing problems in global health. The United States Agency for International Development (USAID) invites organizations and companies to participate with USAID, in cooperation with its partners, to generate novel tools and approaches that accelerate and sustain improved health outcomes in developing countries.	Expression of Interest accepted on a rolling basis though 5/30/22; must be invited for full proposal	Dependent upon proposal and award type	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=305999">https://www.grants.gov/web/grants/view-opportunity.html?opId=305999</a>  (Full Announcement in Related Documents Tab)
21.	Air Force Office of Scientific Research Broad Agency Announcement (DoD)	FA9550-18-S-0003	This BAA's focus is on research areas that offer significant and comprehensive benefits to national warfighting and peacekeeping capabilities. These areas are organized and managed in two scientific branches: Engineering and Information Sciences (RTA) and Physical and Biological Sciences (RTB). Research topics in the Chemistry and Biological sciences categories include Biophysics; Human Performance and Biosystems; Mechanics of Multifunctional Materials and Microsystems; Molecular Dynamics and Theoretical Chemistry; Natural Materials, Systems, and Extremophiles; and Organic Materials Chemistry. For a full list of applicable research topics, see full solicitation.	Proposals accepted on a rolling basis	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=305996">https://www.grants.gov/web/grants/view-opportunity.html?opId=305996</a>  (Full Announcement in Related Documents Tab)

22.	Dept. of the Army, USAMRAA – BAA for Extramural Biomedical Research and Development (DoD)	W81XW H-18-S-SOC1	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel (medical devices, drugs, and biologics) for early intervention in life-threatening injuries, prolonged field care (PFC), human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. The equipment must be easy to use, require minimum maintenance, and have low power consumption. Drugs and biologics should not require refrigeration or other special handling. All materiel and related techniques must be simple and effective, and easily modified for commercialization. Research projects may apply existing scientific and technical knowledge for which concept and/or patient care efficacy have already been demonstrated to meet SOF requirements.</p>	<p>Submissions accepted through 7/31/23</p> <p>Submission of a pre-proposal is required</p>	<p>Dependent upon proposal</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=307754">https://www.grants.gov/web/grants/view-opportunity.html?opId=307754</a></p> <p>(Full Announcement in Related Documents Tab)</p>
23.	Army Applications Lab BAA for Disruptive Applications (DoD)	W911NF-19-S-0004	<p>AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi-domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch.</p>	<p>Submissions accepted through 5/1/24</p> <p>Submission of a pre-proposal is required</p>	<p>Dependent upon proposal</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=315517">https://www.grants.gov/web/grants/view-opportunity.html?opId=315517</a></p> <p>(Full Announcement in Related Documents Tab)</p>
24.	Long Range Broad Agency Announcement (BAA) for Basic and Applied Scientific Research (DoD/NRL)	N00173-19-S-BA01	<p>The Naval Research Laboratory (NRL) The Naval Research Laboratory (NRL) is the Navy’s corporate laboratory. NRL conducts basic and applied research for the Navy in a variety of scientific and technical disciplines. The basic research program is driven by perceptions about future requirements of the Navy. NRL is interested in receiving proposals for Long-Range Science and Technology (S&amp;T) Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. For purposes of this BAA, S&amp;T includes activities involving basic research, applied research, advanced technology development, and, under certain conditions, may include activities involving advanced component development and prototypes.</p>	<p>Submissions accepted through 9/5/20</p>	<p>Dependent upon proposal</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=320355">https://www.grants.gov/web/grants/view-opportunity.html?opId=320355</a></p> <p>(Full Announcement in Related Documents Tab)</p>

25.	Long Range Broad Agency Announcement (BAA) for Navy and Marine Corps Science & Technology (ONR, ONR Global, MCWL) (DoD)	N00014-20-S-B001	<p style="text-align: center;"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>The Office of Naval Research (ONR), ONR Global, and the Marine Corps Warfighting Lab (MCWL) are interested in receiving proposals for Long-Range Science and Technology (S&amp;T) Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. Readers should note that this is an announcement to declare ONR's broad role in competitive funding of meritorious research across a spectrum of science and engineering disciplines. Focus areas for the MCWL solicitation include, but not limited to: Expeditionary Logistics; Interoperable Command and Control (C2) Systems; C2 Afloat or the Naval Operational Architecture; Communications and Networking; Lightening the Load (Technologies that reduce the size and weight of the total load of the Marine Air Ground Task Force, as well as the individual Marine); Counter Improvised Explosive Device (IED) Mine; Persistent Intelligence, Surveillance and Reconnaissance (ISR); Urban Operations; Precision Fired; Cyberspace Operations.</p>	Proposal Due: 9/30/20	Dependent upon proposal	<a href="https://www.onr.navy.mil/-/media/Files/Funding-Announcements/BAA/2020/N00014-20-S-B001.ashx">https://www.onr.navy.mil/-/media/Files/Funding-Announcements/BAA/2020/N00014-20-S-B001.ashx</a>
26.	United States Military Academy Broad Agency Announcement (DoD)	W911NF-20-S-0008	<p>The USMA BAA identifies topics of interest to the USMA departments, directorates, and research centers and institutes. These groups focus on executing in-house research programs, with a significant emphasis on collaborative research with other organizations. The groups fund a modest amount of extramural research in certain specific areas, and those areas are described in this BAA. Proposals are sought for cutting-edge innovative research that could produce discoveries with a significant impact to enable new and improved Army technologies and related operational capabilities and related technologies.</p>	Proposals accepted on a rolling basis	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=325932">https://www.grants.gov/web/grants/view-opportunity.html?opId=325932</a>  (Full Announcement in Related Documents Tab)
27.	Opportunities from the National Virtual Biotechnology Laboratory (NVBL) (DOE)	N/A	<p>The U.S. Department of Energy National Virtual Biotechnology Laboratory (NVBL) is a consortium of DOE National laboratories, each with core capabilities relevant to the threats posed by COVID-19. The NVBL is taking advantage of DOE user facilities, including light and neutron sources, nanoscale science centers, sequencing and bio-characterization facilities, and high-performance computer facilities, to address key challenges in responding to the COVID-19 threat. Examples include developing innovations in testing capabilities, identifying new targets for medical therapeutics, providing epidemiological and logistical support, and addressing supply chain bottlenecks by harnessing extensive additive manufacturing capabilities. The NVBL collaborates extensively with researchers, both in academia and the private sector. In addition, the DOE user facilities are available to users in all sectors of the research community.</p>	N/A	Dependent upon solicitation and proposal	<a href="https://science.osti.gov/nvbl?utm_medium=email&amp;utm_source=FYI&amp;dm_i=1ZJN,6UU9U,RBBVZ,X,RI3TV,1">https://science.osti.gov/nvbl?utm_medium=email&amp;utm_source=FYI&amp;dm_i=1ZJN,6UU9U,RBBVZ,X,RI3TV,1</a>

28.	Broad Agency Announcement (BAA) C4ISR, Information Operations, Cyberspace Operations and Information Technology System Research (DoD)	N66001-20-S-4702	<p align="center"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>The Naval Information Warfare Center, Pacific (NIWC Pacific) is soliciting white papers and proposals in accordance with Federal Acquisition Regulation (FAR) 6.102(d)(2), FAR 35.016 and Department of Defense Grant and Agreement Regulations (DoDGARS) 22.315(a) which provides for competitive selection of basic research, applied research, advanced technology development, and advanced component development and prototype (hereinafter referred to as research). Submissions in response to this announcement shall be for areas relating to the advancement of Command, Control, Communications, Computers, Intelligence, Surveillance, and Reconnaissance (C4ISR) capabilities, enabling technologies for Information Operations and Cyberspace Operations, and Information Technology systems. Accordingly, proposals selected for award are considered to be the result of full and open competition and fully compliant with PL 98-369, "The Competition in Contracting Act of 1984." This BAA is for procurement contracts (hereinafter referred to as contracts), grants, cooperative agreements, and other transactions. Proposed research should investigate unique and innovative approaches for defining and developing next generation integratable C4ISR capabilities and command suites.</p>	White Papers Due: 6/4/21	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=327529">https://www.grants.gov/web/grants/view-opportunity.html?opId=327529</a>  (See Related Documents Tab for Full Announcement)
29.	Broad Agency Announcement (BAA) Biological Technologies (DoD/DARPA)	HR00112 OS0044	The mission of BTO is to foster, demonstrate, and transition breakthrough research, discoveries, and applications that integrate biology, engineering, computer science, mathematics, and the physical sciences. BTO's research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, microbes as production platforms, and deep exploration of changing ecologies and environments on U.S. capabilities and resilience. BTO's programs operate across a wide range of scales, from individual cells to the warfighter to global ecosystems. BTO responds to the urgent and long-term needs of the Department of Defense (DoD) and addresses national security priorities. See Full Announcement for complete list of topics	Abstracts and proposals accepted on rolling basis until 4/22/21	Dependent upon proposal	<a href="https://beta.sam.gov/opp/4efd37762ed0475d871af927279f010d/view">https://beta.sam.gov/opp/4efd37762ed0475d871af927279f010d/view</a>

30.	US Army Combat Capabilities Development Command Broad Agency Announcement (DoD)	W911QY 20R0022	<p align="center"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. This posting is not for a specific requirement - only to post the BAA solicitation so that interested parties can submit white papers and proposals for grants and other assistance agreements.</p>	Proposals accepted on a rolling basis	Dependent on proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=327285">https://www.grants.gov/web/grants/view-opportunity.html?opId=327285</a>  (See Related Documents Tab for Full Announcement)
31.	Airman Readiness Medical Research (ARMR) Hybrid BAA (DoD)	FA8650-20-S-6008	The Warfighter Medical Optimization Division (RHM) intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance.	White papers accepted on rolling basis until 4/30/26	Up to \$49 million per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=327332">https://www.grants.gov/web/grants/view-opportunity.html?opId=327332</a>  (See Related Documents Tab for Full Announcement)
32.	Aerospace Medicine, Clinical Research, Human Performance, and Expeditionary Medicine Broad Agency Announcement (DoD)	BAA-AFRL-RQKHC-2016-0009	The Air Force Research Laboratory (AFRL) 711 Human Performance Wing in the School of Aerospace Medicine and Human Systems Integration Directorate conducts basic and applied research, advanced technology development, as well as test and evaluation to: (1) support the health and performance of Airmen performing across dynamic domains of air, space, and cyber operations, (2) bring innovative techniques and technology into the operational environment to improve outcomes and, (3) provide the Air Force with expertise in Human Systems Integration to ensure weapons systems are designed, developed, or adapted with human capabilities and limitations in mind. 711 HPW solicits innovative research proposals in the following five research areas: 1. Force Health Protection, 2. EN Route Care, 3. Operational Medicine, 4. Expeditionary Medicine, 5. Human Performance and Systems Integration - Maximizing operational human performance for a fit and healthy force.	White papers accepted on rolling basis until 3/1/21	Up to \$20 million per proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=281919">https://www.grants.gov/web/grants/view-opportunity.html?opId=281919</a>  (See Related Documents for Full Announcement)

33.	Defense Sciences Office Office-wide BAA (DoD/DARPA)	HR00112 OS0048	<p align="center"><b>BROAD AGENCY ANNOUNCEMENTS</b></p> <p>The mission of the Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) is to identify and create the next generation of scientific discovery by pursuing high-risk, high-payoff research initiatives across a broad spectrum of science and engineering disciplines and transforming these initiatives into disruptive technologies for U.S. national security.</p>	Proposals accepted on a rolling basis until 6/11/21	Dependent upon proposal	<a href="https://beta.sam.gov/opp/36d6bc789b364142a0f7a267017b06d9/view">https://beta.sam.gov/opp/36d6bc789b364142a0f7a267017b06d9/view</a>
34.	Transforming the Battlespace BAA (DoD/DARPA)	HR00112 OS0053	The Tactical Technology Office (TTO) of DARPA is soliciting executive summaries, proposal abstracts and proposals for applied research, advanced technology development, and platform demonstrations that aim to enable disruptive capabilities for future warfare. TTO projects usually define a reference operational system upfront, decompose critical technical risks, and define a demonstration around them. Use of off-the-shelf technology for lower risk subsystems reduces program cost and schedule but allows critical technologies to be matured and demonstrated.	Proposals accepted on a rolling basis until 6/11/21	Dependent upon proposal	<a href="https://beta.sam.gov/opp/03eeb369da1c4c0ea55ff4d1baed15af/view">https://beta.sam.gov/opp/03eeb369da1c4c0ea55ff4d1baed15af/view</a>
35.	Broad Agency Announcement Verified Security and Performance Enhancement of Large Legacy Software (V-SPELLS) (DoD/DARPA)	HR00112 OS0058	The goal of the V-SPELLS program is to create a developer-accessible capability for piece-by-piece enhancement of software components with new verified code that is both correct-by-construction and compatible-by-construction, i.e., safely composable with the rest of the system. V-SPELLS will create practical tools for developers to gain benefits of formal software verification in incremental software (re)engineering rather than only in clean-slate introduction. V-SPELLS tools will enable developers to deliver assured incremental modernization of legacy systems in a manner that leverages verification technologies and reduces rather than raises risk. V-SPELLS aims to radically broaden adoption of software verification by enabling incremental introduction of superior technologies into systems that cannot be re-designed from scratch and replaced as a whole.	Proposal Due: 9/9/20	Dependent upon proposal	<a href="https://beta.sam.gov/opp/7dc5798bf5e74d8aa3df767edd3e0815/view">https://beta.sam.gov/opp/7dc5798bf5e74d8aa3df767edd3e0815/view</a>



<b>BURN INJURY (1)</b>						
36.	Planar Delivery Platform for Cerium and Silver Into Burn Wounds Request for Project Information (RPI) (DoD/MTEC)	MTEC-20-18-Burns	The USAISR is seeking technology input(s) for the development and fabrication of a planar system for the delivery of cerium and silver to burn wounds. The delivery system must be stable, light weight, small footprint, and easy to deploy by medical and non-medical personnel for treating burn wounds at or near the point of injury under prolonged field care. The following criteria must be met: Planar delivery platform (e.g., textile). SEMI-SOLID FORMULATIONS WILL NOT BE CONSIDERED; Conformable to various body and wound surface contours and anatomical structures and suited for the treatment of severe burn wounds; Controlled and continuous release of CN and silver to burned human or animal skin for a minimum of 72 hours; Scalable and cost-effective manufacturing process; Stable during storage and operation (based on ICH Guidelines).	RPI Due: 9/1/20	N/A	<a href="https://www.mtec-sc.org/wp-content/uploads/2020/08/20-18-Burns_RPI.pdf">https://www.mtec-sc.org/wp-content/uploads/2020/08/20-18-Burns_RPI.pdf</a>
<b>CANCER (16)</b>						
37.	Pre-Announcement FY20 Rare Cancers Research Program (RCRP) (DoD/CDMRP)	N/A	The RCRP aims to improve outcomes for people with rare cancer through discovery and community building, and expansion of knowledge across the cancer landscape. The program mission is to elevate rare cancers research to enable clinically impactful discoveries for the benefit of Service members, their families, Veterans, and the American public. There will be three different award mechanisms: Concept Award, Idea Development Award, and Resource and Community Development Award. Click <a href="#">here</a> to explore the focus areas for each award.	To be announced	Up to \$600,000, for up to 3 years depending on award mechanism	<a href="https://cdmrp.army.mil/pubs/press/2020/20rcrppreann">https://cdmrp.army.mil/pubs/press/2020/20rcrppreann</a>
38.	Participant Engagement and Cancer Genome Sequencing (PE-CGS): Research Centers (U2C Clinical Trial Optional) (NIH)	RFA-CA-19-045	This FOA is associated with the <a href="#">Beau Biden Cancer MoonshotSMInitiative</a> that is intended to accelerate cancer research. Specifically, this FOA falls under a scientific priority designated by the Blue Ribbon Panel (BRP) as <a href="#">Recommendation A "Establish a Network for Direct Patient Engagement"</a> .	Letter of Intent Due: 9/30/20  Proposal Due: 10/30/20	Up to \$2.5 million per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/rfa-ca-19-045.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/rfa-ca-19-045.html#_Section_II_Award_1</a>

39.	Limited Competition: International Agency for Research on Cancer (IARC) Monographs Program (R01 Clinical Trial Not Allowed) (NIH)	RFA-CA-20-045	<p style="text-align: center;"><b>CANCER</b></p> <p>This limited competition FOA solicits the renewal application for the International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Hazards to Humans. The IARC Monographs program, which is supported in part by the NCI, critically evaluates the published scientific evidence on carcinogenic hazards to humans. Monograph volumes are considered critical references that inform health policy and cancer research worldwide about carcinogenic hazards to reduce cancer burden globally.</p>	Proposal Due: 12/16/20	Up to \$793,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-045.html#SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-045.html# Section II. Award 1</a>
40.	Pre-Announcement Promoting Cancer Surveillance Workforce, Education, and Data Use (CDC)	CDC-RFA-DP21-2104	This NOFO will build upon the success of the National Program of Cancer Registries (NPCR) by expanding opportunities to enhance registrars' capacity, resources to support recruitment and retention and promote cancer surveillance data. Moreover, the iteration of this project will build upon the DP16-1605 and the successes and lessons learned from that project. The strengthening of the cancer surveillance workforce in this project will bolster NPCR registries' capacity to comply with Public Law 102 – 51	Estimated Post Date: 9/25/20  Estimated Proposal Due Date: 11/24/20	Up to \$500,000, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328155">https://www.grants.gov/web/grants/view-opportunity.html?opId=328155</a>
41.	Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01/R21 Clinical Trial Not Allowed) (NIH)	PAR-20-276; 277	Through this FOA, the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.).	Proposal Due: 10/5/20 2/5/21 6/5/21 (R01)  10/16/20 2/16/21 6/16/21 (R21)	Up to \$350,000 per year, for up to 5 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-276.html#SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-276.html# Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-277.html#SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-277.html# Section II. Award 1</a>

42.	NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed) (NIH)	PAR-20-278	<p style="text-align: center;"><b>CANCER</b></p> <p>This FOA invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques.</p>	<p>Letter of Intent Due: 10/5/20</p> <p>Proposal Due: 11/6/20</p>	Up to \$600,000 per year, for up to 7 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-278.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-278.html#_Section_II._Award_1</a>
43.	Pre-Announcement Reducing Inequities in Cancer Outcomes through Community-Based Interventions on Social Determinants of Health (CDC)	RFA-DP-21-003	This research NOFO seeks to answer the question, how can we address disparities in cancer outcomes through community-based interventions on social determinants of health? The activities in the NOFO will be conducted under three separate Components of funding: Component A: Primary Cancer Prevention, Component B: Cancer Screening and Component C: Health and Wellbeing of Cancer Survivors – to conduct evaluation research on an innovative, multi-sector intervention to address barriers to health and well-being among cancer survivors from one or more socially or economically disadvantaged populations. This research will generate knowledge about the implementation, impact, and causal mechanisms of the intervention’s effect on the health and wellbeing of cancer survivors. Applicants may apply for one Component (Component A or Component B or Component C).	<p>Estimated Post Date: 12/2/20</p> <p>Estimated Proposal Due Date: 2/10/21</p>	Up to \$1 million, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328316">https://www.grants.gov/web/grants/view-opportunity.html?opId=328316</a>
44.	Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) (NIH)	PAR-20-271	Through this FOA, NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set; and 4) hit-to-lead optimization.	<p>Letter of Intent Due: 9/5/20 1/5/21 5/5/20</p> <p>Proposal Due: 10/5/20 2/5/21 6/5/21</p>	Dependent upon proposal, for up to 4 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-271.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-271.html#_Section_II._Award_1</a>

45.	Pre-Announcement New Cohorts to Assess Environmental Exposures and Cancer Risk (UG3/UH3 Clinical Trial Optional) (NIH)	NOT-CA-20-086	<p style="text-align: center;"><b>CANCER</b></p> <p>The National Cancer Institute (NCI) intends to promote a new initiative by publishing a FOA to solicit applications for innovative scientific research to address knowledge gaps between environmental exposures and cancer etiology across diverse populations using new prospective cohort studies, which will be facilitated by a Coordinating Center that is expected to be awarded under a separate RFA (see the parallel notice of intent to publish announcement NOT-CA-20-091).</p>	<p>Estimated Post Date: 11/1/20</p> <p>Estimated Proposal Due Date: 1/29/21</p>	Up to \$1.3 million, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328521">https://www.grants.gov/web/grants/view-opportunity.html?opId=328521</a>
46.	Pre-Announcement Coordinating Center for New Cohorts to Assess Environmental Exposures and Cancer Risk (U24 Clinical Trial Not Allowed) (NIH)	NOT-CA-20-091	The National Cancer Institute (NCI) intends to promote a new initiative by publishing a FOA to solicit applications for a Coordinating Center to facilitate coordination across approximately five cohorts that are expected to be awarded under a separate RFA (see the parallel notice of intent to publish announcement NOT-CA-20-086). The Coordinating Center will be supported by a U24 award. This Notice is being provided to allow potential applicants time to develop responsive projects and meaningful collaborations.	<p>Estimated Post Date: 11/1/20</p> <p>Estimated Proposal Due Date: 1/29/21</p>	Up to \$800,000, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328522">https://www.grants.gov/web/grants/view-opportunity.html?opId=328522</a>
47.	Pre-Announcement, Glioblastoma Therapeutics Network (U19 Clinical Trial Required) (NIH)	NOT-CA-20-073	The goal of this FOA is to improve the treatment of adult glioblastoma (GBM) by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them in the clinic. Successful early stage trials of these new drugs would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms.	<p>Estimated Post Date: 9/1/20</p> <p>Estimated Proposal Due Date: 11/15/20</p>	Up to \$1.6 million, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328520">https://www.grants.gov/web/grants/view-opportunity.html?opId=328520</a>

48.	Core Infrastructure Support for Cancer Epidemiology Cohorts (U01 Clinical Trial Not Allowed) (NIH)	PAR-20-294	<p style="text-align: center;"><b>CANCER</b></p> <p>Through this FOA, the National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support the basic maintenance activities of an existing CEC prospectively following: 1) study participants to examine associations between exposures and cancer incidence and/or outcomes or 2) cancer patients/survivors to examine exposures or factors associated with cancer progression, recurrence, mortality, incidence of new cancers, or other cancer/health-related outcomes.</p>	Proposal Due: 11/12/20 4/9/21	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-294.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-294.html#_Section_II._Award_1</a>
49.	Cancer SBIR Program Solicitation PHS 2021-1 (NIH/CDC)	PHS 2021-1	This solicitation contains opportunities to submit a proposal under a variety of different Topics. Some Topics allow for only a Phase I proposal to be submitted at this time. Some Topics allow for only a Phase II proposal to be submitted, through the 'Direct to Phase II' process. <b>Click <a href="#">here</a> for a full list of topics.</b>	Proposal Due: 10/26/20	Up to \$400,000 for up to 9 months (Phase I) & up to \$2 million for up to 2 years (Phase II)	<a href="https://sbir.cancer.gov/sites/default/files/Solicitation%20PHS2021-1.pdf">https://sbir.cancer.gov/sites/default/files/Solicitation%20PHS2021-1.pdf</a>
50.	Notice of Information: FNIH Cancer Steering Committee Project Concepts for Novel Biomarker Platforms in Understanding Tumor Heterogeneity (NIH)	NOT-CA-20-092	The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) is issuing a Request for Proposals (RFP) for novel biomarker platforms to support the mission of the BC Cancer Steering Committee (CSC) High Content Data Integration Working Group (HCDI WG). The HCDI WG invites investigators to submit brief project concept proposals for application of novel biomarker platforms to either of two clinical challenges. These proposals will be considered for funding under the BC precompetitive project model. The working group is currently focused on identifying precompetitive, testable technical solutions with potential for commercialization that address the characterization of tumor heterogeneity.	Proposals accepted on a rolling basis until 8/31/20	N/A	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-092.html">https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-092.html</a>

51.	3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed) (NIH)	RFA-CA-20-042	<p style="text-align: center;"><b>CANCER</b></p> <p>Through this FOA, the NCI as a part of its <a href="#">Beau Biden Cancer Moonshot Initiative</a> invites submission of applications requesting support for projects that will accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) as Recommendation I: <i>Generation of Human Tumor Atlases</i>. The overarching goal of this FOA is to accelerate research efforts conducted and led by the Human Tumor Atlas Network (HTAN, <a href="http://humantumoratlas.org">humantumoratlas.org</a>) via the implementation of three-dimensional (3D) imaging technologies that will allow for a comprehensive view of the dynamic multidimensional ecosystems that define tumors in humans.</p>	<p>Letter of Intent Due: 10/9/20</p> <p>Proposal Due: 11/9/20</p>	Up to \$250,000 per year, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-042.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-042.html#_Section_II._Award_1</a>
<b>CENTRAL NERVOUS SYSTEM (5)</b>						
52.	NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional) (NIH)	PAR-20-285	This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the <a href="#">NIH StrokeNet</a> .	<p>Proposal Due: 10/14/20</p> <p>2/18/21</p> <p>6/18/21</p>	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/par-files/PAR-20-285.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/par-files/PAR-20-285.html#_Section_II._Award_1</a>
53.	NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional) (NIH)	RFA-NS-21-001	This FOA invites applications for the Morris K. Udall Centers of Excellence for Parkinson's Disease Research program. The overarching goal of this program is to support specialized research Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinson's disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Applicants will identify an overall research theme that directly addresses a critical challenge in PD research.	<p>Letter of Intent Due: 8/28/20</p> <p>Proposal Due: 9/28/20</p>	Up to \$1.5 million per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-21-001.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-21-001.html#_Section_II._Award_1</a>

54.	NINDS Exploratory Grant Program in Parkinson's Disease Research (P20- Clinical Trial Optional) (NIH)	RFA-NS-21-002	<b>CENTRAL NERVOUS SYSTEM</b> This FOA invites Exploratory Grant (P20) applications for the planning and initiation of collaborative efforts to advance Parkinson's Disease (PD) research. The goal of this program is to formalize new collaborative directions and/or novel interdisciplinary teams to address critical gaps in PD research and to establish a rigorous foundation of research discovery leading directly to an <a href="#">NINDS Morris K. Udall Center of Excellence</a> (P50) application.	Letter of Intent Due: 8/28/20  Proposal Due: 9/28/20	Up to \$300,000 per year, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-002.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-002.html#_Section_II._Award_1</a>
55.	Cellular and Molecular Biology of Complex Brain Disorders (R01/R21 Clinical Trial Not Allowed) (NIH)	PAR-20-263 (R01)  PAR-20-264 (R21)	This FOA encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term complex can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays.	Proposal Due: 10/5/20 2/5/21 6/5/21 (R01)  Proposal Due: 10/16/20 2/16/20 6/16/20 (R21)	Dependent upon proposal, for up to 5 years (R01)  Up to \$275,000, for up to 2 years (R21)	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-263.html">https://grants.nih.gov/grants/guide/pa-files/PAR-20-263.html</a> (R01)  <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-264.html">https://grants.nih.gov/grants/guide/pa-files/PAR-20-264.html</a> (R21)
<b>COMBAT READINESS (1)</b>						
56.	FY20 Combat Readiness-Medical Research Program (CRRP) (DoD/CDMRP)	W81XW H-20-S-CRRP	Focus areas for the CRRP include: Multiple-use scalable wound-care solutions that can address prevention of bleeding and infection, delivery of therapeutics, and promotion of healing spanning the operational medical care continuum or roles of care (e.g., acute through chronic care); Repair and/or restoration of combat-related genitourinary organ and tissue damage; Solutions for assessment of mild traumatic brain injury (mTBI) in deployed and far-forward settings, to include portable devices; Freeze-dried plasma and platelets for hemorrhage control and resuscitation; Solutions to enhance Warfighter readiness in battlefield and austere environments including the prevention and treatment of the following: Gastrointestinal illness such as Enterotoxigenic Escherichia coli diarrheal disease and inflammatory bowel disease, Sleep disorders, Myalgic encephalomyelitis/chronic fatigue syndrome, and Infectious diseases; and Enhanced delivery and utilization of telemedicine platforms.	Pre-Proposal Due: 9/10/20  Proposal Due: 12/3/20	Up to \$2 million, for up to 2 years	<a href="https://cdmrp.army.mil/funding/pa/FY20-CRRP-RDTRA.pdf">https://cdmrp.army.mil/funding/pa/FY20-CRRP-RDTRA.pdf</a>

CORONAVIRUS (15)						
57.	Pre-Announcement SARS-CoV-2 (COVID-19) Program Activities (HHS/OASH)	OS-PAW-20-001	The Office of the Assistant Secretary for Health (OASH) has established the Laboratory and Diagnostics Working Group (LDWG) seeking submissions to a Broad Agency Announcement (BAA) “to prevent, prepare for, and respond to coronavirus, domestically or internationally, for necessary expenses to research, develop, validate, manufacture, purchase, administer, and expand capacity for COVID–19 tests to effectively monitor and suppress COVID–19...” (Paycheck Protection Program and Healthcare Enhancement Act (P.L. 116-139)). OASH/LDWG seeks proposals for projects that will further enable the coordination and development of testing and associated products that meet the current and future needs, and the effective transition of technology into broad use without impediments. The primary areas of focus should specifically include (1) Scaling and Networking of Technologies, and (2) Testing Demonstrations & Technical Assistance. Specifically, OASH is interested in submissions that will substantially increase our testing capacity and quality in the near term, and do not fall within the scope of other HHS programs.	To be determined	Up to \$25 million, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328065">https://www.grants.gov/web/grants/view-opportunity.html?opId=328065</a>
58.	Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional) (NIH)	RFA-DK-20-021	The purpose of this FOA is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases.	Letter of Intent Due: 11/16/20  Proposal Due: 12/16/20	Up to \$250,000 per year, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-021.html#SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-021.html# Section II. Award 1</a>



59.	Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed) (NIH)	PAR-20-256	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.</p>	Proposals accepted on a rolling basis	Dependent upon proposal, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-256.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-256.html#_SectionII.Award1</a>
60.	Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NIH)	NOT-AI-20-059 PA-20-135	NIAID is allowing the submission of applications for Competitive Revisions to active grants to increase and enhance select research efforts to facilitate the Federal SARS-CoV-2/COVID-19 research response. Investigators interested in responding to this NOSI are strongly encouraged to contact the program officers to discuss the proposed project in the context of the parent award and the limited and specific NIAID needs identified above.	Proposals accepted on a rolling basis until 7/2/21	Dependent upon proposal	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-059.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-059.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html#_SectionII.Award1</a>

61.	Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required) (NIH)	RFA-TR-20-003	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.</p>	Applications accepted on a rolling basis	Up to \$3 million per year, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-20-003.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-20-003.html#_SectionII.Award1</a>
62.	Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed) (NIH)	RFA-OD-20-017	This FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e., scents or odors) emanating from skin or exhaled breath, saliva and different oral tissues from the oral cavity. These sensing devices must be able to associate VOC patterns to patients with symptomatic and asymptomatic COVID-19.	Letter of Intent Due: 8/16/20  Proposal Due: 9/18/20	Dependent upon proposal, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-017.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-017.html#_SectionII.Award1</a>
63.	Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed) (NIH)	RFA-OD-20-019	This FOA seeks to fund a single cooperative agreement for a RADx-rad Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. The RADx-rad Data Coordination Center (DCC) will provide overarching support and guidance to RADx-rad awardees in the following three areas: (1) Administrative Operations and Logistics, (2) Data Collection, Integration and Sharing, and (3) Data Management and Use.	Letter of Intent Due: 8/31/20  Proposal Due: 9/30/20	Up to \$4 million, for up to 4 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-019.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-019.html#_SectionII.Award1</a>

64.	Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44/Fast-Track STTR Clinical Trial Not Allowed)	RFA-OD-20-020; 21	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>The goal of this RFA is to solicit Direct to Phase II SBIR and Fast-Track STTR applications to advance development of novel, non-traditional, safe and effective biosensing and detection approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses.</p>	<p>Letter of Intent Due: 8/18/20</p> <p>Proposal Due: 9/18/20</p>	<p>Up to \$1.7 million, for up to 3 years</p> <p>Dependent upon award mechanisms</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-020.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-020.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-021.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-021.html#_Section_II._Award_1</a></p>
65.	Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed) (NIH)	RFA-OD-20-015	<p>This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. As one of the programs within the <a href="#">NIH Rapid Acceleration of Diagnostics-Radical (RADx-rad) program</a> the RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) FOA will support wastewater-based testing (WBT) surveillance which can provide detailed mapping of the extent and spread of COVID-19.</p>	<p>Letter of Intent Due: 8/15/20</p> <p>Proposal Due: 9/18/20</p>	<p>Up to \$2 million per year, for up to 2 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-015.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-015.html#_Section_II._Award_1</a></p>
66.	Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed) (NIH)	RFA-OD-20-014	<p>This RFA will support the early stage development of an innovative platform that integrates biosensing with touchscreen or other digital devices to achieve detection and tracing of SARS-CoV-2 in real-time. Projects are expected to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, sensor functionality, and automatic detection by touchscreen or other digital devices. To achieve the goal of this FOA, the proposed project needs to be milestone driven and carried out by a multidisciplinary team with complementary expertise.</p>	<p>Letter of Intent Due: 8/21/20</p> <p>Proposal Due: 9/15/20</p>	<p>Up to \$300,000 per year, for up to 2 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-014.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-014.html#_Section_II._Award_1</a></p>

67.	Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kids) (R61/R33 Clinical Trial Optional) (NIH)	RFA-OD-20-023	<p style="text-align: center;"><b>CORONAVIRUS</b></p> <p>This FOA seeks to support innovative research to develop novel, new or unique and non-traditional approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify and characterize the spectrum of SARS CoV-2 associated illness, including the multisystem inflammatory syndrome in children (MIS-C) and, through a prognostic algorithm, predict the longitudinal risk of disease severity after a child is exposed to and may be infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes.</p>	Letter of Intent Due: 8/30/20  Proposal Due: 9/30/20	Up to \$3 million, for up to 4 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-023.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-023.html#_Section_II._Award_1</a>
68.	Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional) (NIH)	RFA-OD-20-016	This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions, including residential, with a high density of individuals who are together for prolonged periods of time.	Letter of Intent Due: 8/30/20  Proposal Due: 9/30/20	Dependent upon proposal, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-016.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-016.html#_Section_II._Award_1</a>
69.	Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)(NIH)	RFA-OD-20-018	This FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020. NIH requires that all projects funded under this FOA will actively coordinate, collaborate, and share data with the RADx-rad Data Coordinating Center, as allowed, and with considerations under tribal IRB processes, as appropriate. Researchers applying to this funding opportunity are strongly encouraged to review the companion Data Coordinating Center (DCC) funding opportunity announcement.	Letter of Intent Due: 8/18/20  Proposal Due: 9/18/20	Dependent upon proposal, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-018.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-018.html#_Section_II._Award_1</a>

70.	Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional) (NIH)	RFA-OD-20-022	<b>CORONAVIRUS</b> This FOA seeks applications to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests.	Proposal Due: 9/15/20	Up to \$750,000, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-022.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-022.html#_Section_II._Award_1</a>
<b>CYBERINFRASTRUCTURE &amp; CYBERSECURITY (1)</b>						
71.	Computational and Data-Enabled Science and Engineering (NSF)	PD-20-8084	Advanced computational infrastructure and the ability to perform large-scale simulations and accumulate massive amounts of data have revolutionized scientific and engineering disciplines. The goal of the CDS&E program is to identify and capitalize on opportunities for major scientific and engineering breakthroughs through new computational and data analysis approaches.	Proposal due between 9/1/20 – 11/6/20	Dependent upon proposal	<a href="https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=504813">https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=504813</a>
<b>DIETETICS (1)</b>						
72.	Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed) (NIH)	PA-20-252	This FOA builds on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of analytical methods for dietary supplements and other natural products. The method(s) proposed for validation must be used to identify and/or quantify dietary supplement-relevant ingredients or constituents (i.e., active or marker chemical compounds, adulterants, contaminants) or their metabolites in experimental reagents, raw materials, and/or clinical specimens (e.g., urine or plasma samples).	Proposal Due: 10/15/20 1/15/21 4/15/21	Up to \$100,000, for 1 year	<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-252.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-252.html#_Section_II._Award_1</a>

ENVIRONMENTAL HEALTH (4)						
73.	Notice of Special Interest (NOSI): Stimulating Intervention Research to Reduce Cardiopulmonary Impacts of Particulate Matter in Air Pollution among High-Risk Populations (NIH)	NOT-HL-20-788  PA-20-183; 184; 185	The purpose of this trans-NIH Notice of Special Interest (NOSI) is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Environmental Health Sciences (NIEHS) have special interest in applications aiming to investigate the impact of personal interventions to reduce exposure to particulate matter (PM) in air pollution on cardiovascular and pulmonary (cardiopulmonary) outcomes.	Proposals accepted on a rolling basis until 9/8/25	Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-788.html">https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-788.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-183.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-184.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-20-185.html#_Section_II._Award_1</a>
EPILEPSY (1)						
74.	Pre-Announcement Improving Epilepsy Education, Systems of Care, and Health Outcomes through National and Community Partnerships (CDC)	CDC-RFA-DP21-2101	This NOFO will implement strategies based on three CDC/National Center for Chronic Disease Prevention and Health Promotion domains (Environmental Approaches, Health Care Systems Interventions, and Community Programs Linked to Clinical Services) and will target social determinants of health in order to: Improve health, social participation, and quality of life for people with epilepsy. · Reduce stigma. · Increase access to health services, community resources, and self-management supports. The NOFO will fund two types of recipients: a national organization to provide programs and services in at least 25 states, and 1-3 organizations to work in specific geographic locations (e.g. community; state; region).	Estimated Post Date: 1/11/21  Estimated Proposal Due Date: 4/5/21	Up to \$5 million, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328415">https://www.grants.gov/web/grants/view-opportunity.html?opId=328415</a>

GENETICS & GENOMICS (10)						
75.	Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R01/R21/R03 Clinical Trial Optional) (NIH)	20-254 255; 257	This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Three different funding mechanisms are available: R01, R21, and R03	Proposal Due: 10/19/20 2/17/21 6/17/21	Dependent on proposal, for up to 5 years  Dependent on award mechanisms	<a href="https://grants.nih.gov/grants/guide/pa-files/par-20-254.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/par-20-254.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/par-20-255.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/par-20-255.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/par-20-257.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/par-20-257.html#_Section_II._Award_1</a>
76.	Investigator-Initiated Research on Genetic Counseling Processes and Practices (R01/R21 Clinical Trial Optional) (NIH)	RFA-HG-20-048; 049	The purpose of this initiative is to support investigator-initiated research on genetic counseling processes and practices in genomic medicine. Research is needed to optimize the genetic counseling process in the context of limited resources. Applications will assess, innovate, scale, and/or research the implementation of novel genetic counseling practices to address the need for more healthcare professionals trained in genetic counseling; the uneven access to in-person genetic counseling across U.S. health care systems; and the challenges of effective and efficient communication of genomic findings to clinicians, patients, and families.	Letter of Intent Due: 9/28/20 6/8/21  Proposal Due: 10/28/20 7/8/21	Up to \$500,000 per year, for up to 4 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-048.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-048.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-049.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-049.html#_Section_II._Award_1</a>
77.	BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 - Clinical Trial Not Allowed) (NIH)	RFA-DA-21-006	The purpose of this FOA is to develop tools and technologies to conduct scientifically rigorous, ethical, efficient, and cost-effective research, as well as develop necessary infrastructure, that supports germline and somatic transgenic and gene editing studies in the common marmoset ( <i>Callithrix jacchus</i> ). These studies should answer crucial scientific questions that require genetic perturbation in a non-human primate model organism, as well as support the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) goals of understanding the brain in health and disease.	Letter of Intent Due: 9/15/20  Proposal Due: 10/15/20	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-006.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-006.html#_Section_II._Award_1</a>

78.	Systematic Characterization of Genomic Variation on Genome Function and Phenotype, Single-cell Profiling of Regulatory Element and Gene Activity in Relationship to Genome Function (UM/U24 Clinical Trial Not Allowed)	RFA-HG-20-043; 20-045; 20-046	<p style="text-align: center;"><b>GENETICS &amp; GENOMICS</b></p> <p>These FOAs seek applications (1) to experimentally correlate genomic variants with their effects on genomic function, (2) to establish Mapping Centers that will generate single-cell, multi-omic maps of genes and regulatory elements in the human and mouse genomes and (3) to solicit applications for the Genomic Variation and Function Data and Administrative Coordinating Center (DACC).</p>	<p>Letter of Intent Due: 10/4/20</p> <p>Proposal Due: 11/4/20</p>	<p>Up to \$2.5 million per year, for up to 5 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-043.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-043.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-045.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-045.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-046.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-046.html#_Section_II._Award_1</a></p>
79.	Defining Genomic Influence on Gene Network Regulation & Developing Predictive Models of the Impact of Genomic Variation on Function (U01 Clinical Trial Not Allowed) (NIH)	RFA-HG-20-044; 047	These FOAs seek applications for research projects to (1) explore the effects of genomic variation on phenotypes at the network level and (2) Predictive Modeling Projects that will develop and apply innovative computational models to predict the impact of genomic variation on genome function and/or phenotype and generate a catalog of variant effects.	<p>Letter of Intent Due: 10/4/20</p> <p>Proposal Due: 11/4/20</p>	<p>Up to \$900,000 per year, for up to 5 years</p> <p>Dependent on award mechanism</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-044.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-044.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-047.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-047.html#_Section_II._Award_1</a></p>



INFECTIOUS DISEASE (5)						
80.	Pre-Announcement Expanded Surveillance for New Vaccine Preventable Diseases (CDC)	RFA-IP-21-002	The purpose of this NOFO is to solicit applications for a research cooperative agreement that will fund a network of pediatric medical institutions to conduct prospective, active surveillance for acute gastroenteritis (AGE) and acute respiratory illnesses (ARI) in inpatient and emergency department clinical settings, including healthy controls.	Estimated Post Date: 12/1/20  Estimated Proposal Due Date: 2/23/21	Up to \$1 million, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328354">https://www.grants.gov/web/grants/view-opportunity.html?opId=328354</a>
81.	Pre-Announcement Emerging Infections Network - Research for Preventing, Detecting, and Managing Travelers who Acquire Infectious Diseases Abroad (CDC)	RFA-PS-21-004	The purpose of this NOFO is to support research activities that will assist with the prevention, detection, and management of international travelers who become ill during or after travel. The project must have a focus on travel and tropical medicine providers with the capability to participate in research to determine the disease prevention strategies, burden, severity, optimal diagnostics, treatment interventions, and outcomes of infectious diseases acquired while travelling abroad. This research will bridge the gap between clinical medicine and public health by assisting with improving patient care, better understanding the natural history of disease, and implementing optimal diagnostic and treatment strategies, with the ultimate outcome being an advancement in the global health security of the United States.	Estimated Post Date: 10/26/20  Estimated Proposal Due Date: 2/9/21	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328317">https://www.grants.gov/web/grants/view-opportunity.html?opId=328317</a>
82.	Ecology and Evolution of Infectious Diseases (NSF)	20-585	Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies and should focus on the determinants and interactions of transmission among any host species, including but not limited to humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission.	Proposal Due: 11/18/20	Up to \$2.5 million, for up to 5 years	<a href="https://www.nsf.gov/pubs/2020/nsf20585/nsf20585.htm">https://www.nsf.gov/pubs/2020/nsf20585/nsf20585.htm</a>

83.	Pre-Announcement Annual Estimates of Influenza Vaccine Effectiveness for Preventing Medically Attended Laboratory-Confirmed Influenza in the United States (CDC)	RFA-IP-21-005	<p style="text-align: center;"><b>INFECTIOUS DISEASE</b></p> <p>The goal of this NOFO is to: a) support a network of US institutions that can obtain reliable vaccination information for a population, or cohort of individuals; b) provide accurate estimates of the effectiveness of vaccines against respiratory viruses including influenza, SARS-CoV-2 and other respiratory viruses that may emerge; and c) prevent medically attended influenza-associated illness in the population for whom influenza vaccination is recommended.</p>	Estimated Post Date: 11/4/20  Estimated Proposal Due: 1/8/21	Up to \$2.2 million, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328584">https://www.grants.gov/web/grants/view-opportunity.html?opId=328584</a>
84.	NIAID Clinical Trial Planning Grant (R34 Clinical Trials Not Allowed) (NIH)	PAR-20-270	This FOA encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the <a href="#">NIAID website</a> for additional information about the research mission and high-priority research areas of the NIAID.	Letter of Intent Due: 12/12/20 4/12/21  Proposal Due: 1/12/21 5/12/21	Up to \$150,000, for up to 1 year	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-270.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-270.html#_Section II. Award 1</a>
			<b>MATERIALS RESEARCH (3)</b>			
85.	Division of Materials Research: Topical Materials Research Programs: Biomaterials, Condensed Matter Physics, Metals and Metallic Nanostructures, Polymers (NSF)	20-588; 20-589; 20-582	Research supported by the Division of Materials Research (DMR) focuses on advancing fundamental understanding of materials, materials discovery, design, synthesis, characterization, properties, and materials-related phenomena. The Division supports research and education activities in the United States through funding of individual investigators, teams, centers, facilities, and instrumentation. Projects supported by DMR are essential for the development of future technologies and industries that meet societal needs, as well preparation of the next generation of materials researchers. Solicitation 20-589 applies to Biomaterials (BMAT), Condensed Matter Physics (CMP), Metals and Metallic Nanostructures (MMN), and Polymers (POL). Solicitation 20-588 applies to Ceramics (CER), Electronic and Photonic Materials (EPM), and Solid State and Materials Chemistry. Solicitation 20-582 applies to Condensed Matter and Materials Theory (CMMT)	Proposals accepted on rolling basis until 11/2/20	Dependent upon proposal	<a href="https://www.nsf.gov/pubs/2020/nsf20588/nsf20588.htm">https://www.nsf.gov/pubs/2020/nsf20588/nsf20588.htm</a>  <a href="https://www.nsf.gov/pubs/2020/nsf20589/nsf20589.htm">https://www.nsf.gov/pubs/2020/nsf20589/nsf20589.htm</a>  <a href="https://www.nsf.gov/pubs/2020/nsf20582/nsf20582.htm">https://www.nsf.gov/pubs/2020/nsf20582/nsf20582.htm</a>

<b>MATERNAL HEALTH (2)</b>						
86.	Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledge and Research Coordination Center (P30 Clinical Trial Not Allowed) (NIH)	RFA-HD-21-025	This FOA invites applications to form the Knowledge and Research Coordination Center (KRCC) of the NICHD's Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub. The MPRINT Hub will serve as a national resource for expertise in maternal and pediatric therapeutics to conduct and foster therapeutics-focused research in obstetrics, lactation, and pediatrics while enhancing inclusion of people with disabilities. The MPRINT KRCC will coordinate and support the operations of the entire MPRINT Hub, interface with Centers of Excellence in Therapeutics (CETs; RFA-HD-21-026) and develop a web portal to access an underlying curated knowledge base of maternal and pediatric pharmacology and therapeutics.	Letter of Intent Due: 10/30/20  Proposal Due 11/30/20	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-21-025.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-21-025.html#_Section_II_Award_1</a>
87.	Pre-Announcement Maternal and Child Health Leadership, Education, and Advancement in Undergraduate Pathways (LEAP) Training Program (HHS/HRSA)	HRSA-21-034	The purpose of the Maternal and Child Health Pipeline Training Program is to promote the development of a culturally diverse and representative health care workforce by recruiting undergraduate training students from economically and educationally disadvantaged backgrounds (including racial and ethnic minorities) into maternal and child health professions.	Estimated Post Date: 10/8/20  Estimated Proposal Due Date: 1/6/21	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328459">https://www.grants.gov/web/grants/view-opportunity.html?opId=328459</a>
<b>MENTAL HEALTH (3)</b>						
88.	Pre-Announcement ALACRITY Centers for Practice-Based Effectiveness and Services Research with Near-Term Impact (P50 Clinical Trial Optional) (NIH)	NOT-MH-20-070	The NIMH intends to reissue and extend the Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Centers program. The ALACRITY Centers program is intended to support high-impact, practice-based research with near-term potential to significantly advance clinical practice and generate knowledge that will fuel transformation of mental health care in the United States.	Estimated Post Date: 8/30/20  Estimated Proposal Due Date: 5/17/21	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328519">https://www.grants.gov/web/grants/view-opportunity.html?opId=328519</a>

89.	Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional) (NIH)	PAR-20-286	<p style="text-align: center;"><b>MENTAL HEALTH</b></p> <p>This FOA invites applications for research centers to support integrated programs of high-impact, practice-based research with near-term potential to address NIMH suicide prevention priorities and help achieve the National Action Alliance for Suicide Prevention goals of reducing the rate of suicide in the US. The Centers are intended to support transdisciplinary teams of clinical and mental health services researchers, behavioral/social scientists, health information and communications technologists, health systems engineers, decision scientists, and mental health stakeholders (e.g., service users, family members, clinicians, payers) engaged in transdisciplinary programs of research that could not be achieved using standard research project grant mechanisms.</p>	<p>Letter of Intent: 9/19/20, 4/26/21</p> <p>Estimated Proposal Due Date: 10/19/20, 5/26/21</p>	<p>Up to \$2 million per year, for up to 5 years</p>	<p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-286.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-286.html#_Section_II._Award_1</a></p>
90.	Pre-Announcement Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide RPG (R01/R34 Clinical Trial Optional) (NIH)	NOT-MH-20-068; 069	<p>The NIMH intends to promote a new initiative by publishing a FOA to solicit applications for research on service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services.</p>	<p>Estimated Post Date: 11/16/20</p> <p>Estimated Proposal Due Date: 2/14/21</p>	<p>Dependent upon proposal</p>	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328531">https://www.grants.gov/web/grants/view-opportunity.html?opId=328531</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328528">https://www.grants.gov/web/grants/view-opportunity.html?opId=328528</a></p>
<b>MUSCULAR DYSTROPHY (1)</b>						
91.	Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional) (NIH)	RFA-AR-21-008	<p>The purpose of this FOA is to publicize a competition for Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRCs). These Centers promote collaborative basic, translational, and clinical research and provide important resources that can be used by the national muscular dystrophy research communities. The Centers also provide outstanding environments for the training of new researchers capable of addressing high priority research objectives in the muscular dystrophies. Center investigators are expected to participate in important community outreach efforts to increase awareness of their research activities in the patient and advocacy communities and to incorporate community perspectives into the conduct of patient-centered research.</p>	<p>Letter of Intent Due: 9/19/20</p> <p>Proposal Due: 10/19/20</p>	<p>Up to \$1 million per year, for up to 4 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-21-008.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-21-008.html#_Section_II._Award_1</a></p>

NEPHROLOGY (7)						
92.	Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) – Clinical Centers & Scientific and Data Research Center (U01 Clinical Trial Required) (NIH)	RFA-DK-20-011; 012	Acute kidney injury (AKI) is associated with high morbidity, including increased risk of chronic kidney disease (CKD), end-stage kidney disease (ESKD), cardiovascular disease, and mortality. Severity, duration, and frequency of episodes of AKI as well as age, pre-existing CKD, and other comorbidities are associated with greater risks of CKD progression and death. There is limited evidence to inform recommendations for processes of care or therapeutic interventions targeting progression of kidney disease and the associated morbidity and mortality in AKI survivors. This is a missed opportunity to prevent chronic disease and premature death. The Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium, composed of 3 to 4 Clinical Centers (CCs) and a Scientific and Data Research Center (SDRC), will develop and test interventions that aim to reduce morbidity compared with usual care in Stage 2 and 3 AKI survivors.	Letter of Intent Due: 10/4/20  Proposal Due: 11/4/20	Dependent upon proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-011.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-011.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-012.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-012.html</a>
93.	Pre-Announcement Supporting and Improving the Surveillance System for Chronic Kidney Disease in the United States (CDC)	CDC-RFA-DP21-2107	This award will build upon the previous CKD surveillance work to continue supporting, updating, and improving the CKD Surveillance System with relevant data sources and indicators, to enhance the CKD Surveillance System website with state-of-the-art technologies and visualization tools, and to assist CDC, prevention researchers, policy makers, medical practitioners, and states in developing and evaluating programs and policies to better prevent, detect, and manage CKD.	Estimated Post Date: 9/29/20  Estimated Proposal Due Date: 11/28/20	Up to \$1.2 million, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=328301">https://www.grants.gov/web/grants/view-opportunity.html?oppId=328301</a>

94.	Chronic Kidney Diseases of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium - Field Epidemiology Sites, Renal Science Core, Scientific Data Coordinating Center (SDCC) (U01/U24 - Clinical Trial Not Allowed) (NIH)	RFA-DK-20-017; 018; 019	<p style="text-align: center;"><b>NEPHROLOGY</b></p> <p>This FOA invites applications for a Field Epidemiology Sites (FES), a Renal Science Core (RSC), &amp; a Scientific Data Coordinating Center (SDCC) to study Chronic Kidney Disease of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE). The Consortium will consist of a Scientific Data Coordinating Center (SDCC), Field Epidemiology Sites (FES), a Renal Science Core (RSC), and the Human Health Exposure Analysis Resource (HHEAR). The Consortium will work together to finalize ethical epidemiology research designs, execute common strategies for biological sampling and environmental assessment, apply the best analytic strategies for collected samples and data, and disseminate results to the global research and public health communities. The final design of the study, as determined by the Steering Committee, may significantly vary from individual applications. It is required that all funded sites fully abide with the final harmonized design set by the Consortium Steering Committee.</p>	<p>Letter of Intent Due: 10/10/20</p> <p>Proposal Due Date: 11/10/20</p>	<p>Dependent upon proposal, for up to 5 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-017.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-017.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-018.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-018.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-019.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-019.html#_Section_II._Award_1</a></p>
95.	NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed) (NIH)	RFA-DK-20-024	<p>The NIDDK Catalyst Award is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK's Division of Digestive Diseases and Nutrition. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere.</p>	<p>Letter of Intent Due: 12/6/20</p> <p>Proposal Due Date: 1/6/21</p>	<p>Up to \$500,000 per year, for up to 5 years</p>	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-024.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-024.html#_Section_II._Award_1</a></p>

<b>PAIN MANAGEMENT (2)</b>						
96.	Notice of Special Interest (NOSI): Discovery of Analgesic Natural Products through the NINDS IGNITE Program (NIH)	NOT-AT-20-016  PAR-18-762	For this NOSI, NCCIH is interested in supporting research geared toward development of robust, validated analgesic assays suitable for medium- to high-throughput screening of natural product libraries. For the purposes of this NOSI, natural products are defined as extracts, chromatographic fractions, or isolated constituents derived from herbal, botanical, marine, microbial, or animal sources. For this NOSI, NCCIH is prioritizing analgesic targets relevant to musculoskeletal, neuropathic, and inflammatory pain conditions.	Proposal Due: 10/20/2021/17/21	Up to \$750,000, for up to 3 years	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AT-20-016.html">https://grants.nih.gov/grants/guide/notice-files/NOT-AT-20-016.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/par-18-762.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/par-18-762.html#_Section_II_Award_1</a>
<b>PATIENT CENTERED RESEARCH (4)</b>						
97.	Pre-Announcement Broad PCORI Funding Announcements – Cycle 3 2020 (for Addressing Disparities, Assessment of Options, Communication and Dissemination Research, Improving Healthcare Systems) (PCORI)	N/A	The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research. This PFA covers the following four priority areas: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research, and Improving Health Systems. These broad areas encompass the patient-centered comparative CER we support. PCORI plans to release a range of funding announcements and evidence products in these areas in the next several years, starting with: Increasing Access to and Continuity of Patient-Centered Maternal Care and Improving Care for Individuals with Intellectual and/or Developmental Disabilities Growing into Adulthood.	Letter of Intent Due: 9/29/20  Proposal Due: 1/12/21	Up to \$5 million, for up to 5 years  Dependent upon award mechanism	<a href="https://www.pcori.org/funding-opportunities/announcement/broad-pcori-funding-announcements-cycle-3-2020">https://www.pcori.org/funding-opportunities/announcement/broad-pcori-funding-announcements-cycle-3-2020</a>
98.	Pre-Announcement Implementation of Findings from PCORI's Major Research Investments -- Cycle 3 2020 (PCORI)	N/A	This PFA seeks to fund meaningful implementation projects that promote the uptake of peer-reviewed findings from specific, high-priority PCORI initiatives—in the context of the body of related evidence—and make these findings more actionable and accessible to patients, clinicians, or other targeted decision makers and healthcare stakeholders at the point of care or in other decision settings.	Letter of Intent Due: 9/21/20  Proposal Due: 12/1/20	Up to \$2.5 million, for up to 3 years	<a href="https://www.pcori.org/funding-opportunities/announcement/implementation-findings-pcori-major-research-investments-cycle-3-2020">https://www.pcori.org/funding-opportunities/announcement/implementation-findings-pcori-major-research-investments-cycle-3-2020</a>

99.	Pre-Announcement Improving Methods for Conducting Patient-Centered Outcomes Research -- Cycle 3 2020 (PCORI)	N/A	<b>PATIENT CENTERED RESEARCH</b> In this PCORI Funding Announcement (PFA), PCORI aims to fund studies that address high-priority methodological gaps in patient-centered outcomes research (PCOR) and comparative clinical effectiveness research (CER).PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by PCOR/CER studies. Research area of interest include methods related to: Ethical and Human Subjects Protections Issues in PCOR/CER; Improve Study Design; Support Data Research Networks; and Improve the Use of Artificial Intelligence and Machine Learning (NEW)	Letter of Intent Due: 9/29/20  Proposal Due: 1/12/21	To be announced	<a href="https://www.pcori.org/funding-opportunities/announcement/improving-methods-cycle-3-2020">https://www.pcori.org/funding-opportunities/announcement/improving-methods-cycle-3-2020</a>
100.	Pre-Announcement Implementation of PCORI- Funded Patient- Centered Outcomes Research Results – Cycle 3 2020 & Cycle 1 2021 (PCORI)	N/A	The intent of this limited PFA is to move evidence developed with PCORI research funding toward practical use in improving health care and health outcomes. PCORI will fund projects that aim to implement patient-centered clinical comparative effectiveness research (CER) results obtained from PCORI-funded studies in real-world practice settings, and, in selected cases, projects that focus on the dissemination of these findings. This limited PFA gives PCORI investigators the opportunity—following the generation of results from their PCORI-funded research award—to propose the next step(s) for making their research results more useful, actionable, accessible, and available to targeted end-users of these findings.	Letter of Intent Due: 9/22/20, 1/26/21  Proposal Due: 12/1/20; 4/6/21	Up to \$1 million, for up to 3 years	<a href="https://www.pcori.org/funding-opportunities/announcement/limited-pfa-implementation-pcor-results-cycle3-2020">https://www.pcori.org/funding-opportunities/announcement/limited-pfa-implementation-pcor-results-cycle3-2020</a>  <a href="https://www.pcori.org/funding-opportunities/announcement/limited-pfa-implementation-pcor-results-cycle1-2021">https://www.pcori.org/funding-opportunities/announcement/limited-pfa-implementation-pcor-results-cycle1-2021</a>
<b>PEDIATRICS (5)</b>						
101.	Pre-Announcement HEALTHy Brain and Child Development Study (NIH)	NOT-DA- 20-069	The primary objective of the HBCD Project is to conduct a large scale multi-site longitudinal study that can prospectively examine human brain, cognitive, behavioral, social, and emotional development beginning at birth and extending through middle childhood. The study will comprise a normative sample that represents the diversity of pregnant women in the US population, a cohort of women who have used opioids and other substances during pregnancy will also be recruited, and a comparison group from similar backgrounds/environments as the cohort of women who have used substances.	Estimated Post Date: 11/1/20  Estimated Proposal Due Date: 3/1/21	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328523">https://www.grants.gov/web/grants/view-opportunity.html?opId=328523</a>



102.	Pre-Announcement Promoting the Importance of Infant and Childhood Vaccination Among Pregnant Women by Prenatal Care Providers (CDC)	RFA-IP-21-001	<p style="text-align: center;"><b>PEDIATRICS</b></p> <p>The purpose of this NOFO is to investigate the acceptability, feasibility, and effectiveness of promoting infant immunization during prenatal care visits, leading parents to vaccinate their children confidently. Prenatal care providers, including obstetricians and midwives, are trusted sources of information for pregnant women, yet many feel uncomfortable providing information or discussing concerns about infant vaccination because they may consider this to be outside of their area of expertise. This represents a significant missed opportunity to provide important information to pregnant women/parents from a trusted source at a critical time when research suggests opinions about childhood vaccination are forming.</p>	<p>Estimated Post Date: 11/9/20</p> <p>Estimated Proposal Due Date: 1/25/21</p>	Up to \$500,000, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328395">https://www.grants.gov/web/grants/view-opportunity.html?opId=328395</a>
103.	Notice of Special Interest (NOSI): Improving Methods to Assess Body Composition in Infants and Young Children (NIH)	NOT-DK-20-036 PA-19-270; 272	<p>This Notice invites SBIR and STTR applications that seek to fill technological gaps in assessment of body composition and its distribution in infants and/or young children from birth through 5 years. Research proposing to conduct interventions designed to alter body composition in children or proposing the development of norms for lean body mass and adiposity in young children using existing technologies would not be appropriate for this Notice. Applications proposing to conduct animal research are also not appropriate. Applications for this initiative should be submitted using the following FOAs: PA-19-270; PA-19-272, through the expiration date of this notice.</p>	Proposals accepted on a rolling basis until 9/5/22	Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-036.html">https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-036.html</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-19-270.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-19-270.html#_Section II. Award 1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-19-272.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PA-19-272.html#_Section II. Award 1</a>

<b>RARE DISEASES (2)</b>						
104.	Pre-Announcement Characterizing the Natural History of Fragile X Syndrome to Inform the Development of Intervention Outcome Measures (CDC)	RFA-DD-21-002	The purpose of this NOFO is to conduct research to better characterize the natural history of fragile X syndrome (FXS) and meaningful outcome measures in order to improve the lives of children and adolescents with FXS with and without autism spectrum disorder (ASD). The funding will support enrollment and in-person standardized assessments of individuals aged 6 through 19 years with full-mutation FXS, which can include new and previously enrolled study participants of the Fragile X Online Registry with Accessible Research Database (FORWARD). FORWARD is a national registry of patients enrolled in FXS specialty clinics who are part of the Fragile X Clinical and Research Consortium.	Estimated Post Date: 11/10/20  Estimated Proposal Due Date: 1/20/21	Up to \$700,000, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328398">https://www.grants.gov/web/grants/view-opportunity.html?opId=328398</a>
105.	Development of Standard Core Clinical Outcomes Assessments (COAs) and Endpoints (UG3/UH3 Clinical Trial Optional) (FDA)	RFA-FD-21-004	The purpose of this FOA is to solicit applications for UG3/UH3 cooperative agreements to support the development of a publicly available core set(s) of COAs and their related endpoints for specific disease indications or for disease impacts that span multiple rare diseases of similar phenotypes.	Letter of Intent Due: 8/21/20  Proposal Due: 10/14/20	Up to \$2.7 million, for up to 4 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-21-004.html#SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-21-004.html# Section II. Award 1</a>
<b>REGENERATIVE MEDICINE (1)</b>						
106.	FY20 Reconstructive Transplant Research Program (RTRP) Investigator-Initiated Research Award (IIRA) (DoD/CDMRP)	W81XWH-20-RTRP-IIRA	The RTRP seeks vascularized composite allotransplantation (VCA)-focused research, also known as composite tissue allotransplantation. To meet the intent of the FY20 RTRP Investigator-Initiated Research Award mechanism, applicants must address at least one of the following FY20 RTRP Focus Areas: Reduce the risks of VCA-associated immunosuppression; Develop reliable non-invasive methods or tools for monitoring VCA graft rejection; Advance existing or develop innovative ex vivo tissue preservation strategies to extend the timeline between procurement and transplantation	Pre-Application Due: 8/19/20  Proposal Due: 11/12/20	Up to \$1.5 million, for up to 3 years	<a href="https://cdmrp.army.mil/funding/pa/FY20-RTRP-IIRA.pdf">https://cdmrp.army.mil/funding/pa/FY20-RTRP-IIRA.pdf</a>

<b>REPRODUCTIVE HEALTH (1)</b>						
107.	Fertility Status as a Marker for Overall Health (R01/R21 Clinical Trial Optional) (NIH)	PAR-20-281; 282	The purpose of this FOA is to support research that explores the premise that fertility status can be a marker for overall health and focuses on studies evaluating fertility as a marker for overall health, and therefore applications that look at the effects of the disease or disorder on fertility are outside of the scope of this program. Recruitment of new cohorts will not be supported by this FOA.	Letter of Intent Due: 9/19/20 5/19/21  Proposal Due: 10/19/20 6/19/21	Dependent on proposal, for up to 5 years  Dependent upon award mechanism	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-281.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-281.html#_Section_II._Award_1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/par-20-282.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/par-20-282.html#_Section_II._Award_1</a>
<b>RESEARCH INTEGRITY (1)</b>						
108.	Pre-Announcement Anticipated Availability of Funds for Research on Research Integrity (HHS/OASH)	IR-ORI-21-001	This notice solicits applications for projects that will conduct innovative research that advances the evolving field of research integrity and develops the evidence base for the research integrity community. ORI seeks to fund original research related to the prevention of research misconduct, facilitation of whistleblowing and the protection of whistleblowers, and promote the responsible conduct of research and the furtherance of research integrity in the United States and internationally. ORI also intends to support efforts to create or enhance educational and interventional programs for promoting research integrity and preventing research misconduct. In furtherance of this effort, ORI is also soliciting applications for projects to develop and evaluate programs and resources related to the prevention of research misconduct, protection of whistleblowers, and the furtherance of research integrity in the United States and internationally.	Estimated Post Date: 7/31/20  Estimated Proposal Due Date: 4/5/21	Up to \$150,000, per award	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328454">https://www.grants.gov/web/grants/view-opportunity.html?opId=328454</a>

			<b>SBIR/STTR (2)</b>			
109.	PHS 2020-2 Omnibus Solicitation for SBIR and STTR Grant Applications (Parent STTR [R41/R42] and Parent SBIR [R43/R44] Clinical Trial Required/Not Allowed) (NIH)	PA-20-261; 262; 265; 260	Small business concerns that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, or FDA awarding components identified in this FOA are encouraged to submit SBIR/STTR grant applications that will be accepted and considered in any area within the mission of the <a href="#">Components of Participating Organizations</a> .	Proposal Due: 9/5/20 1/5/21 4/5/21	Up to \$256,680 for up to 1 year for Phase I & up to \$1.7 million for up to 2 years for Phase II	<a href="https://grants.nih.gov/grants/guide/pa-files/pa-20-261.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/pa-20-261.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-262.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-262.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-265.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-265.html#_SectionII.Award1</a>  <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-260.html#_SectionII.Award1">https://grants.nih.gov/grants/guide/pa-files/PA-20-260.html#_SectionII.Award1</a>

110.	SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Dependent Upon Award Mechanism (NIH)	PAR-20-128; 129; 130	<p style="text-align: center;"><b>SBIR/STTR</b></p> <p>These FOAs are to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOAs aim to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts.</p>	<p>Letter of Intent Due: 12/5/20 3/5/21</p> <p>Proposal Due: 1/5/21 4/5/21</p>	<p>Up to \$3.4 million, mechanism, for up to 3 years</p> <p>Depending upon award mechanism</p>	<p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-128.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-128.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-129.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-129.html#_Section_II._Award_1</a></p> <p><a href="https://grants.nih.gov/grants/guide/pa-files/par-20-130.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/pa-files/par-20-130.html#_Section_II._Award_1</a></p>
			<b>SCLERODERMA (2)</b>			
111.	FY20 Scleroderma Research Program (SRP) (DoD/CDMRP)	W81XW H-20-SRP-IDA; TRPA	<p>The SRP provides two funding mechanisms: 1. The Idea Development Award promotes ideas that are still in the early stages of development and have the potential to yield high-impact findings and new avenues of investigation and supports conceptually innovative high-risk/high-reward research that could lead to critical discoveries or major advancements in scleroderma research and/or improvements in patient care. 2. The Translational Research Partnership Award supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in scleroderma into clinical applications and supports the development of translational research collaborations between two or more investigators to address a central problem or question in scleroderma in a manner that would be less readily achievable through separate efforts.</p>	<p>Pre-Application Due: 9/9/20</p> <p>Proposal Due: 12/4/20</p>	<p>Up to \$750,000, for up to 5 years</p> <p>Dependent upon award mechanism</p>	<p><a href="https://cdmrp.army.mil/funding/pa/FY20-SRP-IDA.pdf">https://cdmrp.army.mil/funding/pa/FY20-SRP-IDA.pdf</a></p> <p><a href="https://cdmrp.army.mil/funding/pa/FY20-SRP-TRPA.pdf">https://cdmrp.army.mil/funding/pa/FY20-SRP-TRPA.pdf</a></p>

SICKLE CELL DISEASE (2)						
112.	Demonstration to Increase Hydroxyurea Prescribing for Children with Sickle Cell Disease Through Provider Incentives (HHS/OMH)	MP-CPI-20-002	This notice solicits applications to demonstrate the feasibility and effectiveness of providing financial incentives to providers to improve the quality of life of children with sickle cell disease (SCD) through increased prescription rates of hydroxyurea. OMH intends projects funded under this initiative to build the capacity of State Medicaid Offices and other partners to achieve three main goals: (1) develop performance measures for hydroxyurea prescribing for the three main provider types that care for children with SCD (i.e., hematologists, primary care providers, and emergency clinicians); (2) develop and implement an incentive payment system(s) for each provider type; and (3) evaluate the effectiveness of financial incentives for providers to increase hydroxyurea prescribing and decrease emergency department visits for children with SCD.	Proposal Due Date: 8/27/20	Up to \$1.25 million per year, for up to 3 years	<a href="https://www.grantsolutions.gov/gs/previewPublicAnnouncement.do?id=67220">https://www.grantsolutions.gov/gs/previewPublicAnnouncement.do?id=67220</a>
113.	Pre-Announcement Sickle Cell Disease Newborn Screening Follow-up Program (HHS/HRSA)	HRSA-21-036	The purpose of this program is to provide support for a Sickle Cell Newborn Screening Technical Assistance Center (TAC) that will improve the care and reduce rates of loss to follow-up of individuals identified with sickle cell disease (SCD) and sickle cell trait through universal newborn screening by supporting efforts of community-based organizations (CBOs) on sickle cell disease education and service coordination.	Estimated Post Date: 1/11/20 Estimated Proposal Due Date: 4/12/21	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=328460">https://www.grants.gov/web/grants/view-opportunity.html?oppId=328460</a>
STEM EDUCATION & WORKFORCE DEVELOPMENT (15)						
114.	NIEHS Research Intensive Short Courses and Educational Opportunities (NIEHS RISE) (R25 Clinical Trial Not Allowed) (NIH)	RFA-ES-20-015	This FOA will support creative educational activities with a primary focus on: <i>Courses for Skills Development</i> . The intent of this FOA is to encourage applications to develop and conduct short-term research education activities with the goal of improving knowledge and skills needed to conduct environmental health research. Short courses submitted under this FOA are expected to include relevant intensive hands-on training in environmental health science topics. In addition to in-person instruction, courses that incorporate innovative or novel education models, such as project-based learning or virtual instruction, are encouraged.	Letter of Intent Due: 10/30/20 Proposal Due: 11/30/20	Up to \$200,000 per year, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-20-015.html#SectionII.Award1">https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-20-015.html# Section II. Award 1</a>

115.	Re-entry to Active Research Program (RARE) (NSF)	20-586	<p><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>The RARE program includes two Tracks to catalyze the advancement of investigators along the academic tenure system after a research hiatus, either to a tenure-track position or to a higher-tenured academic rank. Track 1 of the RARE program reengages investigators in a competitive funding opportunity with accommodations for gap in record that are a result of the research hiatus. Track 2 retrains investigators for whom the research hiatus has led to the need for new or updated techniques, such that retraining is required to return the investigator to competitive research activity.</p>	Proposals accepted on a rolling basis	Up to \$300,000, per award	<a href="https://www.nsf.gov/pubs/2020/nsf20586/nsf20586.htm">https://www.nsf.gov/pubs/2020/nsf20586/nsf20586.htm</a>
116.	National Defense Education Program (NDEP) Request for Information (RFI) for the Office of the Under Secretary of Defense (Research & Engineering) (DoD)	RFI-WHS-07222020	The purpose of this RFI is to survey industry (to include non-profits, academia, large, and small businesses (e.g., 8(a), service-disabled Veteran-owned small business, HUBZone small business, small disadvantaged business, Veteran-owned small business, and woman-owned small business)) for relevant information. This RFI consists of three focus areas, which include: I. Science Technology, Engineering and Mathematics (STEM) education, outreach, and workforce development, II. Biotechnology education and workforce development, and III. Enhanced civics education. Respondents are not required to address all three focus areas, but should direct their responses to one of the areas.	RFI Responses Due: 8/28/20	N/A	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328298">https://www.grants.gov/web/grants/view-opportunity.html?opId=328298</a>  (See Related Documents Tab for Full Announcement)
117.	Louis Stokes Alliances for Minority Participation (LSAMP) (NSF)	NSF 20-590	The overall goal of the program is to assist universities and colleges in diversifying the nation's science, technology, engineering and mathematics (STEM) workforce by increasing the number of STEM baccalaureate and graduate degrees awarded to populations historically underrepresented in these disciplines. LSAMP's efforts to increase diversity in STEM are aligned with the goals of the Federal Government's five-year strategic plan for STEM education, <a href="#">Charting a Course for Success: America's Strategy for STEM Education</a> .	Proposal Due: 11/20/20	Up to \$3.5 million, for up to 5 years	<a href="https://www.nsf.gov/pubs/2020/nsf20590/nsf20590.htm">https://www.nsf.gov/pubs/2020/nsf20590/nsf20590.htm</a>

118.	Pre-Announcement Behavioral Health Workforce Education and Training (BHWET) Program – Paraprofessionals (HHS/HRSA)	HRSA-21-089; 90	<p><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>The purpose of the BHWET Paraprofessionals program is to improve the supply and distribution of behavioral health paraprofessionals fully equipped to practice in integrated, interprofessional team-based settings, trained in high quality services to populations across the lifespan, and working in rural and medically underserved areas.</p>	<p>Estimated Post Date: 11/6/20</p> <p>Estimated Proposal Due Date: 2/4/21</p>	Dependent upon proposal	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328444">https://www.grants.gov/web/grants/view-opportunity.html?opId=328444</a></p> <p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328445">https://www.grants.gov/web/grants/view-opportunity.html?opId=328445</a></p>
119.	FY2021 Department of the Navy (DON) Historically Black Colleges and Universities/Minority Institutions (HBCU/MI) Program (DoD/DON)	N00014-20-S-F007	The Department of Navy (DON) Historically Black Colleges and Universities/Minority Institutions (HBCU/MI) Program aims to increase the quantity and quality of minority professionals in science, technology, engineering, and mathematics (STEM) in the defense community. The technical content of any proposed effort must contribute to the S&T mission and vision of the Department of the Navy and must align with the Naval Research Development Framework.	<p>White Papers Due: 9/15/20</p> <p>Proposal Due: 12/8/20</p>	Up to \$450,000, for up to 3 years	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328543">https://www.grants.gov/web/grants/view-opportunity.html?opId=328543</a></p> <p>(See Related Documents Tab for Full Announcement)</p>
120.	FY 2021 Vannevar Bush Faculty Fellowship (VBFF) (DoD/ONR)	N00014-20-S-F006	The VBFF supports innovative basic research within academia, as well as opportunities intended to develop the next generation of scientists and engineers for the defense workforce. ONR is soliciting proposals for the VBFF program and seeks distinguished researchers for the purpose of conducting innovative basic research in areas of interest to the DoD and fostering long-term relationships between the VBFF Fellows and the DoD.	<p>White Paper Due: 8/26/20</p> <p>Proposal Due: 1/15/21</p>	Up to \$3 million, for up to 5 years	<p><a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328010">https://www.grants.gov/web/grants/view-opportunity.html?opId=328010</a></p> <p>(See Related Documents for Full Announcement)</p>
121.	Transition to Aging Research for Predoctoral Students (F99/K00) (NIH/NIA)	RFA-AG-21-022	The purpose of the Transition to Aging Research Award for Predoctoral Students is to increase, retain, and diversify the pool of trainees in aging and geriatric research. This two-phase award will allow awardees to complete doctoral dissertation projects and provides a variety of training supports to facilitate the smooth transition of doctoral graduates into competitive, aging-focused postdoctoral positions.	Proposal Due: 10/22/20	Up to \$450,000, for up to 5 years	<p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-022.html#_Section_II._Award_1">https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-022.html#_Section_II._Award_1</a></p>



122.	Pre-Announcement BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)" (NIH)	NOT-MH-20-062	<b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b> The NIMH, with other NIH Institutes and Centers participating in the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative, intends to reissue "BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)."	Estimated Post Date: 8/14/20  Estimated Proposal Due Date: 10/8/20	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328526">https://www.grants.gov/web/grants/view-opportunity.html?opId=328526</a>
123.	Pre-Announcement NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Coordination and Evaluation Center & Cohort (U54 Clinical Trial Not Allowed) (NIH)	NOT-RM-20-022; 023	The purpose of this Notice is to inform the research community that the NIH Common Fund, along with its partner NIH Institutes, Centers, and Offices, is planning to issue a FOA to support the NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort & Coordination and Evaluation Center. This will be an open competition.	Estimated Post Date: 9/9/20  Estimated Proposal Due Date: 11/9/20	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328529">https://www.grants.gov/web/grants/view-opportunity.html?opId=328529</a>  <a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328530">https://www.grants.gov/web/grants/view-opportunity.html?opId=328530</a>
124.	Innovations in Graduate Education (IGE) Program (NSF)	20-595	The program seeks proposals that explore ways for graduate students in research-based master's and doctoral degree programs to develop the skills, knowledge, and competencies needed to pursue a range of STEM careers. The program supports testing of novel models or activities with high potential to enrich and extend the knowledge base on effective graduate education approaches. The program addresses both workforce development, emphasizing broad participation, and institutional capacity building needs in graduate education. Strategic collaborations with the private sector, non-governmental organizations (NGOs), government agencies, national laboratories, field stations, teaching and learning centers, informal science centers, and academic partners are encouraged.	Proposal Due: 11/4/20	Up to \$1 million, for up to 5 years	<a href="https://www.nsf.gov/pubs/2020/nsf20595/nsf20595.htm">https://www.nsf.gov/pubs/2020/nsf20595/nsf20595.htm</a>

125.	Mathematical Sciences Infrastructure Program (NSF)	PD-20-1260	<p><b>STEM EDUCATION &amp; WORKFORCE DEVELOPMENT</b></p> <p>The DMS Infrastructure program invites projects that support core research in the mathematical sciences, including: 1) novel projects supporting research infrastructure across the mathematical sciences community; 2) training projects complementing the Workforce Program, and 3) conference, workshop, and travel support requests that include cross-disciplinary activities or have an impact at the national scale.</p>	Proposal Due: 12/15/20 5/11/21	Up to \$50,000, per award	<a href="https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=12756">https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=12756</a>
126.	Research Experiences for Teachers (RET) in Engineering and Computer Science (NSF)	20-584	<p>This program supports active long-term collaborative partnerships between K-12 Science, Technology, Engineering, Computer and Information Science, and Mathematics (STEM) in-service and pre-service teachers, full-time community college faculty, university faculty and students, and industry partners to enhance the scientific disciplinary knowledge and capacity of the STEM teachers and/or community college faculty through participation in authentic summer research experiences with engineering and computer science faculty researchers. The research projects and experiences all revolve around a focused research area related to engineering and/or computer science that will provide a common cohort experience to the participating educators.</p>	Proposal Due: 9/30/20	Up to \$600,000, for up to 3 years	<a href="https://www.nsf.gov/pubs/2020/nsf20584/nsf20584.htm">https://www.nsf.gov/pubs/2020/nsf20584/nsf20584.htm</a>
127.	International Research Experiences for Students (NSF)	20-598	<p>The overarching, long-term goal of the IRES program is to enhance U.S. leadership in science and engineering research and education and to strengthen economic competitiveness through training the next generation of research leaders. This solicitation features two mechanisms; proposers are required to select one of the following tracks to submit their proposal: Track I focuses on the development of world-class research skills in international cohort experiences. Track II is dedicated to targeted, intensive learning and training opportunities that leverage international knowledge at the frontiers of research. Student participants supported by IRES funds must be citizens, nationals, or permanent residents of the United States.</p>	Proposal Due: 11/12/20	Dependent upon proposal	<a href="https://www.nsf.gov/publications/pubsum.jsp?ods_key=nsf20598">https://www.nsf.gov/publications/pubsum.jsp?ods_key=nsf20598</a>

SUBSTANCE USE DISORDERS (2)						
128.	Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional) (NIH)	PAR-20-279	The purpose of this FOA is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA approved device-based treatments for SUDs.	Letter of Intent Due: 11/15/20 7/10/21  Proposal Due: 12/15/20 8/10/21	Up to \$500,000 per year, for up to 2 years (UG3)  Dependent upon proposal, for up to 3 years (UH3)	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-279.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-279.html#_Section_II_Award_1</a>
129.	NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) (NIH)	PAR-20-267	NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing research and also to extend the focus of research to substance use/misuse and addiction.	Letter of Intent Due: 8/25/20  Proposal Due: 9/25/20	Dependent on proposal, for up to 5 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-267.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-267.html#_Section_II_Award_1</a>
THERAPEUTICS (1)						
130.	Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed) (NIH)	PAR-20-253	This FOA encourages applications for NIH Countermeasures Against Chemical Threats ( <b>CounterACT</b> ) exploratory/developmental (R21) projects. Projects supported by this FOA are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement programs or other related initiatives.	Letter of Intent Due: 4/26/21  Proposal Due: 5/26/21	Up to \$275,000, for up to 2 years	<a href="https://grants.nih.gov/grants/guide/pa-files/PAR-20-253.html#_Section_II_Award_1">https://grants.nih.gov/grants/guide/pa-files/PAR-20-253.html#_Section_II_Award_1</a>

TRAUMATIC BRAIN INJURY (2)						
131.	Candidate Acute Traumatic Brain Injury (TBI) Management Capabilities (CATMC) and Acute TBI Diagnostics and Monitoring (ATDM) in Austere Environments (DoD/MTEC)	MTEC-20-15-TBI	This program aims to support the acute diagnostic, therapeutic and management technologies across the spectrum of traumatic brain injury (TBI) severities capable of being used in a far-forward operational environment.: FOCUS AREA #1 (Treatments): Development of an acute treatment (pharmaceutical, technology, etc.) for TBI; FOCUS AREA #2 (Diagnostics): Diagnostic, prognostic and management technologies for acute, early intervention for TBI. This solicitation is not meant to support development of a new prototype but should focus on fine-tuning and optimization of existing prototypes or other technologies. This RPP allows for proposed solutions to be currently at TRL 4 of 5 at the time of submission. It is the goal that proposed projects should achieve TRL 6 by the end of the total program.	Solution Briefs Due: 9/1/20  Must be MTEC member to apply	Up to \$3 million for up to 2 years  Dependent upon achieving TRL 5 or 6.	<a href="https://www.mtec-sc.org/wp-content/uploads/2020/07/MTEC-20-15-TBI_RPP.pdf">https://www.mtec-sc.org/wp-content/uploads/2020/07/MTEC-20-15-TBI_RPP.pdf</a>
132.	Pre-Announcement Warfighter Brain Health (WBH): Late and Long-Term Consequences of Head Impact Exposure and Concussion/Mild Traumatic Brain Injury (mTBI) on Brain Health (DoD/MTEC)	N/A	The overall objective of the WBH program is to advance both knowledge and technology prototypes (i.e., training, tools, and practice guidelines for assessment, metrics, and interventions) that will reduce or eliminate acute to late and long-term effects from single and repetitive concussion/mTBI. The DoD will be seeking Solution Briefs for <i>utilization of an already established and experienced</i> Clinical Consortium (CC) that will follow human subjects who have sustained a single or repeated concussion/mTBI to determine the relationship between concussion/mTBI, head impact exposures and brain health outcomes. The CC will be expected to interact with a Government Steering Committee with involvement from the U.S. Army Medical Research and Development Command (USAMRDC) and other stakeholders. Click <a href="#">here</a> for some desirable capabilities.	To be announced	Dependent upon proposal	<a href="https://www.mtec-sc.org/upcoming-solicitations/">https://www.mtec-sc.org/upcoming-solicitations/</a>

VISION (1)						
133.	Pre-Announcement NEI Audacious Goals Initiative: Translation-Enabling Models to Evaluate Survival and Integration of Regenerated Neurons in the Visual System (U24 Clinical Trial Not Allowed) (NIH)	NOT-EY-20-011	The NEI intends to promote a new initiative by publishing a FOA to solicit applications for research on in vivo models for translation-enabling research related to neural regeneration in the visual system. The complexity of generating new models and testing molecular or cell-based therapies will require collaborative teams with complementary expertise. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in July 2020 with an expected application due date in October 2020. This FOA will utilize the U24 activity code.	Estimated Post Date: 7/28/20  Estimated Proposal Due Date: 10/15/20	Dependent upon proposal	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328525">https://www.grants.gov/web/grants/view-opportunity.html?opId=328525</a>
OTHER (1)						
134.	Small Business Development Centers (SBA)	OSBDC-2021-01	This FOA is open to existing SBDC recipient organization currently funded under the Small Business Development Center (SBDC) program. Selected applicants are required to maximize their efforts to leverage SBA funding by working in conjunction with SBA District Offices and other Federal, state, local and tribal government small business development programs and partners to deliver professional, high quality, individualized business advising and technical assistance to existing small businesses and pre-venture entrepreneurs. SBDCs shall provide problem solving assistance to help small businesses access capital, develop and exchange new technologies, and improve business planning, strategy, operations, financial management, personnel administration, marketing, export assistance, sales and other areas required for small business growth and expansion, management improvement, increased productivity and innovation.	Proposal Due: 9/14/20	Dependent upon proposal, for up to 2 years	<a href="https://www.grants.gov/web/grants/view-opportunity.html?opId=328399">https://www.grants.gov/web/grants/view-opportunity.html?opId=328399</a>  (See Related Documents Tab for Full Announcement)